European evidence based consensus for endoscopy in inflammatory bowel disease  by Annese, Vito et al.
Ava i l ab l e on l i ne a t www.sc i enced i r ec t . com
ScienceDirect
Journal of Crohn's and Colitis (2013) 7, 982–1018CONSENSUS/GUIDELINES
European evidence based consensus for
endoscopy in inflammatory bowel disease
Vito Annesea,⁎,1,2, Marco Dapernob,2, Matthew D. Rutter c,d,2,
Aurelien Amiot e, Peter Bossuyt f, James East g, Marc Ferranteh, Martin Götz i,
Konstantinos H. Katsanos j, Ralf Kießlichk, Ingrid Ordás l, Alessandro Repicim,
Bruno Rosan, Shaji Sebastiano, Torsten Kucharzik p,
Rami Eliakimq,⁎⁎ ,1,2on behalf of ECCOa Dept. Gastroenterology, University Hospital Careggi, Largo Brambilla 3, 50139 Florence, Italy
b S.C. Gastroenterologia, A.O. Ordine Mauriziano, Corso Re Umberto 109, 10128 Torino, Italy
c Tees Bowel Cancer Screening Centre, University Hospital of North Tees, Hardwick Road, TS19 8PE Stockton-on-Tees,
Cleveland, UK
d Durham University, County Durham, UK
e Gastroenterology, CHU Henri Mondor, 51 Av. du Maréchal de Lattre de Tassigny, 94010 Creteil, France
f Gastroenterology, AZ Imeldaziekenhuis, Imeldalaan 9, 2820 Bonheiden, Belgium
g Translational Gastroenterology Unit, Experimental Medicine Division, Nuffield Dept. of Clinical Medicine, Oxford University,
John Radcliffe Hospital, Headley Way, Headington, Oxford OX3 9DU, UK
h Department of Gastroenterology, University Hospital Gasthuisberg, Herestraat 49, 3000 Leuven, Belgium
i Innere Medizin 1, Universitätsklinikum Tübingen, Otfried-Müller-Str. 10, 72076 Tübingen, Germany
j Department of Gastroenterology, Medical School, University of Ioannina, Stavrou Niarxou Avenue, 45110 Ioannina, Greece
k I. Med. Klinik und Poliklinik, Johannes-Gutenberg-Univ. Mainz, Langenbeckstr. 1, 55131 Mainz, Germany
l Department of Gastroenterology, Hospital Clinic Barcelona, c/Villarroel 170, 08036 Barcelona, Spain
m Digestive Endoscopy, IRCCS Humanitas, Via Manzoni 56, 20089 Rozzano, Italy
n Gastroenterology, Centro Hospitalar do Alto Ave, Guimarães, Rua dos Cutileiros, Creixomil, 4835 Guimaraes, Portugal
o Gastroenterology, Hull & East Yorkshire NHS Trust, Anlaby Road, HU3 2JZ Hull, UK
p Innere Medizin und Gastroenterologie, Städtisches Klinikum Lüneberg, Bögelstraße 1, 21339 Lüneburg, Germany
q Gastroenterology, Sheba Medical Center, 52621 Tel Hashomer, IsraelReceived 13 September 2013; accepted 20 September 2013⁎ Correspondence to: V. Annese, Department of Gastroenterology, University Hospital Careggi, Largo Brambilla 3, 500139 Florence, Italy.
⁎⁎ Correspondence to: R. Eliakim, Department of Gastroenterology, Sheba Medical Center, Faculty of Medicine, Tel Aviv University, Tel
Aviv, Israel.
E-mail addresses: annesev@aou-careggi.toscana.it (V. Annese), ramieliakim@yahoo.com (R. Eliakim).
1 AV and RE acted as convenors of the Consensus.
2 VA, MD, MR and RE contributed equally to this work.
1873-9946 © 2013 The Authors. Published by Elsevier B.V. on behalf of European Crohn's and Colitis Organisation.
http://dx.doi.org/10.1016/j.crohns.2013.09.016
Open access under CC BY-NC-ND license.
KEYW
Ulcer
Crohn
Endos
Color
983European evidence based consensus for endoscopy in inflammatory bowel disease5. The final document on each topic was written by the
ORDS & ABBREVIATIONS
ative colitis (UC);
's disease (CD);
copy;
ectal cancer (CRC)chairmen in conjunction with their working party.in isolation. The final text was edited for consistency1. IntroductionEndoscopy plays an essential role in the diagnosis, manage-
ment, prognosis, and surveillance of inflammatory bowel
disease (IBD), but surprisingly there are few available
guidelines.1,2 This prompted the ECCO Guidelines Committee
(GuiCom)members to promote a Consensus on the appropriate
indication and application of different endoscopic modalities
in IBD. Since the development of guidelines is an expensive and
time-consuming process, this Consensus may help to avoid
duplication of effort in the future. It may also identify issues
where the evidence is lacking and controlled studies are
awaited.
The strategy to reach the Consensus involved five steps:
1. Two members of the GuiCom (VA and RE) identified four
main topics: a) Diagnosis and follow-up; b) Score of
endoscopic activity; c) Small bowel endoscopy; and
d) Surveillance. During 2012 a call for participants to
the Guideline was made to ECCO members. In addition,
expert endoscopists recognised for their active research
in the field were invited. Participants were selected by
the Guicom and four working groups were created. Each
working group had a chair (VA, MD, MT, and RE), two
ECCO members including young members (Y-ECCO) and
one experienced endoscopist. For the development of the
guideline, relevant questions on separate topics were
devised by the chairmen and their working parties. The
questions were focused on current practice and areas
of controversy. Participants of the Consensus process
were asked to answer the questions based on evidence
from the literature as well as their experience (Delphi
procedure)3;
2. The working parties working in parallel performed a
systematic literature search of their topic with the
appropriate key words using Medline/Pubmed and the
Cochrane database, as well as other relevant sources;
3. Provisional guideline statements on their topic were
then written by the chairmen. These were circulated
and commented on first by working party members and
then among the applicants not included in the working
groups and the ECCO National representatives (see
Acknowledgement) on a web-based platform (www.
cpg-development-org);
4. The working parties then met in Vienna in January
2013 chaired by VA and RE to revise and agree the
statements. Each statement was projected and revised
until a consensus was reached. Consensus Statement was
reached when there was agreement by N85% of partici-
pants. For each statement the level of evidence (EL) was
given according to the Oxford Centre for Evidence Based
Medicine (Table 1.1)4;Consensus guideline statements in bold are followed by
comments on the evidence and opinion. Statements are
intended to be read in context with the qualifying
comments in the accompanying text and not to be read
of style by VA and RE, before being circulated and
approved by the participants. In some areas, where the
level of evidence is generally low, expert opinion was
included as appropriate.
In addition, ECCO has diligently maintained a disclosure
policy of potential conflicts of interests (CoI). The conflict of
interest declaration is based on a form used by the
International Committee of Medical Journal Editors (ICMJE).
The CoI statement is not only stored at the ECCO Office and
the editorial office of JCC but also open to public scrutiny on
the ECCO website (https://www.ecco-ibd.eu/about-ecco/
ecco-disclosures.html) providing a comprehensive overview
of potential conflicts of interest of the consensus participants
and guideline authors.
2. Diagnosis
2.1. Ileocolonoscopy
ECCO Statement 2A
For suspected IBD, ileocolonoscopy with biopsies is the
preferred procedure to establish the diagnosis and extent
of disease [EL 2] [Voting results: 100% agreement].Ileocolonoscopy represents the most important and potent
tool in the diagnosis of suspected IBD and must be performed
soon after patient referral and possibly before the initiation of
any medical treatment. In Ulcerative colitis (UC) endoscopic
changes characteristically commence proximal to the anal
verge and extend proximally in a continuous, confluent and
concentric fashion. The demarcation between inflamed and
normal areas is usually clear and may occur abruptly,
especially in distal disease.5 Macroscopic and microscopic
rectal sparing has been described in children presenting
with UC prior to treatment.6–9 In adults, a normal or patchy
inflammation in the rectum is more likely due to previous
topical therapy.10 Patchy inflammation in the caecum
referred to as “caecal patch”11,12 is observed in patients
with left-sided colitis. When there is macroscopic and
histological rectal sparing or the presence of a caecal patch in
a newly diagnosed colitis, evaluation of the small bowel in
addition to an ileocolonoscopy is indicated. Appendiceal skip
lesions are reported in up to 75% of patients with UC.13–17 It
has been associated with a better response to medical
therapy17 and a higher risk of pouchitis after ileal pouch
anastomosis.13–17 Continuous extension of macroscopic or
Table 1.1 Levels of evidence based on the 2011 version of Oxford Centre for Evidence Based Medicine (for details see http://www.cebm.net/mod_product/design/ files/CEBM-
Levels-of-Evidence-2.1.pdf).3
Questions Level 1 Level 2 Level 3 Level 4 Level 5
How common is the problem? Local and current random
sample surveys (or censuses)
Systematic review of surveys
that allow matching to local
circumstances a
Local non-random sample a Case-series a n/a
Is this diagnostic or monitoring test
accurate? (Diagnosis)
Systematic review of cross
sectional studies with
consistently applied
reference standard and
blinding
Individual cross sectional
studies with consistently
applied reference standard
and blinding
Non-consecutive studies, or
studies without consistently
applied reference standards a
Case-control studies, or poor
or non-independent refer-
ence standard a
Mechanism-based
reasoning
What will happen if we do not add a
therapy? (Prognosis)
Systematic review of
inception cohort studies
Inception cohort studies Cohort study or control arm
of randomized trial b
Case-series or case control
studies, or poor quality
prognostic cohort study a
n/a
Does this intervention help?
(Treatment Benefits)
Systematic review of
randomized trials or n-of-1
trials
Randomized trial or
observational study with
dramatic effect
Non-randomized controlled
cohort/follow-up study a
Case-series, case-control
studies, or historically con-
trolled studies a
Mechanism-based
reasoning
What are the COMMON harms?
(Treatment harms)
Systematic review of
randomized trials,
systematic review of nested
case-control studies, n-of-1
trial with the patient you are
raising the question about, or
observational study with
dramatic effect
Individual randomized trial
or (exceptionally)
observational study with
dramatic effect
Non-randomized controlled
cohort/follow-up study
(post-marketing surveil-
lance) provided there are
sufficient numbers to rule
out a common harm. (For
long-term harms the duration
of follow-up must be
sufficient.) a
Case-series, case-control, or
historically controlled
studies a
Mechanism-based
reasoning
What are the RARE harms? (Treat-
ment harms)
Systematic review of
randomized trials or n-of-1
trial
Randomized trial or
(exceptionally) observational
study with dramatic effect
Is this (early detection) test
worthwhile? (Screening)
Systematic review of
randomized trials
Randomized trial Non-randomized controlled
cohort/follow-up study a
Case-series, case-control, or
historically controlled
studies a
Mechanism-based
reasoning
a As always, a systematic review is generally better than an individual study.
b Level may be graded down on the basis of study quality, imprecision, indirectness (study PICO does not match questions PICO), because of inconsistency between studies, or because the
absolute effect size is very small; Level may be graded up if there is a large or very large effect size.
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985European evidence based consensus for endoscopy in inflammatory bowel diseasehistological inflammation from the caecum into the most
distal ileum defined as ‘backwash ileitis’ is observed in up to
20% of patients with pancolitis18,19 and is associated with a
more refractory course of disease.20
The endoscopic hallmark of Crohn's disease (CD) is the
patchy distribution of inflammation with skip lesions (areas
of inflammation interposed between normal appearing
mucosa). CD ulcers tend to be longitudinal and may be
associated with a cobblestone appearance of the ileum or
colon, fistulous orifices and strictures. Rectal sparing is
often encountered and circumferential, continuous inflam-
mation is rare. Biopsy specimens taken from the edges of
ulcers and aphthous erosions maximise the possibility
of discovering granulomas which are pathognomonic in
CD.21,22
There is no consensus on whether IBD patients undergo-
ing colonoscopy are at increased risk of complications.
When there is severe, active disease in both CD and UC,
the value of full colonoscopy is counterbalanced by a
higher risk of bowel perforation. Older age, severe disease,
steroid use, female gender and endoscopic dilations
appeared to be associated with an increased risk of
perforation (0.3% to 1%).23,24 In these circumstances,
initial flexible sigmoidoscopy is safer and ileocolonoscopy
should be postponed until the clinical condition improves.
However, a more recent study in a referral centre cohort
suggested that the risks are not increased in experienced
hands.252.2. Upper GI endoscopyECCO Statement 2B
Upper GI endoscopy is routinely performed in assessment
of paediatric and adolescent IBD to accurately classify
IBD [EL3]. While upper GI endoscopy and biopsies may be
useful in all patients at diagnosis to evaluate the
extension and disease location, whether it should be
performed routinely in asymptomatic adult patients
remains unclear [EL5] [Voting results: 100% agreement].Upper gastrointestinal (GI) tract inflammation has become
increasingly recognised, even in the absence of specific
localizing symptoms in IBD patients. The Montreal classifi-
cation system and its modified version for paediatric use
(Paris classification)26 allowed classification of upper GI
involvement in CD, independent of other locations. Upper
GI endoscopy is mandatory in the paediatric population with
suspected IBD where growth failure matters, for differen-
tiating between UC and CD and to confirm a diagnosis of
CD.27,28
In adult IBD, there are no specific recommendations.
However, CD patients with dyspepsia, abdominal pain andvomiting would benefit from an upper GI endoscopy.29
Upper GI endoscopy may also be important in specific cases
to establish the diagnosis of Crohn's disease, to assess
disease extension and severity and to aid in tailoring
therapy.30 However, a minority of UC patients may also
have upper GI tract inflammation, manifesting as diffuse
duodenitis or gastritis, characterised by oedema, erythe-
ma, erosions and thickened mucosal folds.31 Finally, upper
GI endoscopy is mandatory in patients with suspected
concomitant coeliac disease.32
2.3. Quality of endoscopy in IBD patients
Although currently no special certification to perform endos-
copy in IBD patients is required, the consensus recommends
that gastroenterologists performing endoscopy in IBD patients
should be experienced and adequately trained in recognizing
endoscopic patterns in IBD.33 This is to assure consistency,
quality and safety.
A standard terminology to describe IBD lesions during
endoscopy is important. So far, common agreement has been
reached by previous ECCO consensus about frequently used
endoscopic terms. Substantial work has been recently done
on endoscopic assessment and descriptors in UC,34,35 with
subsequent validation.36,37 The arbitrariness of some of the
definitions is recognised but the consensus supported the
agreed terminology (Table 2.1).
Endoscopy in children and adolescents should be
performed with deep sedation or general anesthesia, by
expert endoscopists based on national recommendations in a
setting that is suitable for diagnosing and treating children
and adolescents with IBD.382.4. Endoscopic biopsies in IBD
ECCO Statement 2C
For a reliable diagnosis of CD and UC multiple biopsies
from six segments (terminal ileum, ascending, transverse,
descending, sigmoid and rectum) should be obtained.
Multiple biopsies imply a minimum of two representative
samples from each segment including macroscopically
normal segments [EL2] [Voting results: 100% agreement].
Normal mucosal biopsies effectively exclude active IBD.
For IBD diagnosis multiple representative biopsies in a
standard protocol are needed. At least two biopsies from
five sites around the colon including the rectum and
terminal ileum, if possible, should be taken. Biopsies
should be representative from areas of minor and major
inflammation to mirror correctly the intensity and spec-
trum of inflammation. In addition, biopsies must be taken
also from ‘normal appearing’ mucosa.22 Targeted biop-
sies from areas of stenosis, from any unusual polypoid
lesions or from any other lesion that may attract the
endoscopists' attention should be labeled in separate
bottles. Biopsies should always be accompanied by de-
tailed clinical information to aid the histopathologist to
986 V. Annese et al.provide an accurate diagnosis. It is important to consider
that histological activity may correlate poorly with
clinical and endoscopic activity. For more detailed infor-
mation on this issue refer to the forthcoming ECCO Path-
ologic Consensus on IBD.39
2.5. Follow-up: need for repeat scope and biopsies
2.5.1. Uncertain diagnosis
ECCO Statement 2D
When diagnosis remains in doubt, repeat endoscopic
and histologic assessment is appropriate. Investigation
may include repeat ileocolonoscopy, upper GI endos-
copy, wireless capsule endoscopy or enteroscopy [EL5]
[Voting results: 100% agreement].
One of the pitfalls in diagnosing IBD is the failure to con-
sider other diseases. In 10% of adult patients the diagnosis
will be changed to CD or vice versa and the diagnosis of IBD
discounted during the first 5 years after symptom onset.40
Diagnostic misclassification has been documented in
patients enrolled in IBD genetic studies and frequently
involves assigning the diagnosis of IBD to non-affected
individuals.41 In addition undifferentiated colitis accounts
for about 5% of initial diagnoses of IBD.42 In about 80%
of patients with undifferentiated colitis at presentation,
a diagnosis of either UC or CD is made within 8 years
of follow up on reevaluation and some clinical and
demographic features can help in identifying the final
diagnosis.422.5.2. Repeat endoscopy during remission
ECCO Statement 2E
Routine endoscopy for patients in clinical remission is
unnecessary, unless it is likely to change management
[EL5] [Voting results: 100% agreement].
The appropriateness of periodic endoscopic reassessment
after index colonoscopy has never been formally studied
and the value of it is much debated.43 However, endo-
scopy could be used for disease monitoring and reassess-
ment may help to optimise management strategies in
a given patient. Disease extent and activity influence
medical management, including choice of medical therapy
and the route of administration. In addition, there is
evidence that with immunosuppressive treatment, partic-
ularly with anti-TNFα agents, long-term mucosal healing
can be achieved and this may affect the outcome in
IBD.44–49Endoscopy is still considered the standard for evaluating
disease activity, it is used to confirm mucosal healing,
but it is invasive and costly. Increased faecal levels of
calprotectin and lactoferrin have been used more recently
as surrogate markers of active inflammation.50 As is the case
for the more traditionally used inflammatory marker serum
CRP, faecal markers may not be elevated in some patients
with endoscopically active disease. This is more likely in
ileal compared to colonic disease.51–54 However, the
sensitivity of raised faecal markers (60–70%) in predicting
endoscopically active disease is superior to that of serum
CRP and CDAI.52 Björkesten CG et al.53 prospectively
collected data from 210 endoscopies in 64 CD patients
treated with anti-TNFα agents. Neither the clinical indices
nor CRP were reliable at identifying endoscopic remission,
however raised calprotectin had a sensitivity of 84%
and specificity of 74%. In the study by D'Haens et al.54 a
calprotectin level of ≤250 μg/g predicted endoscopic
remission (CDEIS ≤3) with sensitivity 94.1%, specificity
62.2%, PPV 48.5% and NPV 96.6%. Recent studies emphasise
the value of calprotectin in assessing disease severity
(correlating with endoscopic indices), diagnosing relapse and
response to treatment in UC.55,56 In summary, faecal levels of
calprotectin or lactoferrin are emerging as a surrogate marker
of mucosal healing and may reduce the need for endoscopic
reassessments.
Clinical remission may not be associated with endo-
scopic or histological remission, but the prognostic impli-
cations of endoscopic re-evaluation in quiescent disease
have yet to be determined and formally investigated.
Recently the Italian Group for IBD reported a multicentre
study in 81 consecutive patients with mild to moderate UC.
All patients received an endoscopic evaluation 6 weeks
following treatment with oral plus topical mesalazine.
Sixty-one (75%) of patients achieved clinical remission, but
five of them (8%) were not in endoscopic remission. Interest-
ingly, the cumulative relapse rate at 1 year was 23% in
patients with both clinical and endoscopic remission com-
pared to 80% (p b 0.0001) in patients with only clinical
remission.57
2.5.3. Repeat endoscopy to change management
ECCO Statement 2F
Endoscopic reassessment should be considered in cases of
relapse, refractoriness, new symptoms, or when surgery
is considered [EL5] [Voting results: 100% agreement].
The usefulness of endoscopic reassessment should be eval-
uated on a case by case basis in patients not responding
to therapy, those with frequent relapse, or steroid-
dependency, and in general terms when a significant change
to medical management is contemplated. This is often the
case in paediatric IBD, as the overall rate of management
change after endoscopic evaluation can be in up to 42% of
cases.58 In both CD and UC a number of population-based and
cohort studies have demonstrated the relevance of endoscopic
Table 2.1 Terminology of endoscopic lesions in IBD.
Mucosal damage Description Grading
Loss of vascular pattern Loss of normal mucosal appearance without
well-demarcated, arborizing capillaries
From patchy or blurred to complete loss
Erythema Unnaturally reddened mucosa From discrete or punctiform to diffuse erythema
Granularity Mucosal pattern produced by a reticular
network of radiolucent foci of 0.5–1 mm of
diameter with a sharp light reflex
From fine to coarse or nodular, due to abnormal
light reflection
Friability/bleeding Bleeding or intramucosal haemorrhage before
or after the passage of the endoscope
From contact bleeding (bleeding with light
touch) to spontaneous bleeding
Erosion A definite discontinuation of mucosa less than
3 mm in size. Also described as pinpoint ulceration
Isolated, diffuse
Aphthous ulcer White depressed center surrounded by a halo of
erythema; (some consider this synonymous with
‘erosion’)
Isolated, multiple
Ulcer Any lesion of the mucosa of unequivocal depth,
with or without reddish halo
Isolated or multiple based on morphology:
circular, linear, stellar, serpiginous, irregular
shape Superficial or deep
Ulcer size (no underscore) Defined in mm or classified as: ≤5 mm;
5–20 mm; N20 mm
Diffuse, mucosal abrasion with residual mucosa
producing a polypoid appearance
Ulcer depth (no underscore) Shallow (localized to submucosa)—no border
Deep (beyond muscularis propria)—e.g. edges
elevated N1 mm
Stenosis Narrowing of the lumen Single, multiple, passable (by standard adult
endoscope), un-passable, passable after dilation
Ulcerated, non-ulcerated
Post-inflammatory polyps
(previously ‘pseudopolyp’)
Polypoid lesion, usually small, glistering, isolated
or multiple, scattered throughout the colon.
Sometimes cylindrical or giant (N2 cm) in size
Isolated, diffuse, occluding (‘giant’)
Cobblestone Mucosal pattern with raised nodules, resembling
the paving of a “Roman” road
With or without ulceration
987European evidence based consensus for endoscopy in inflammatory bowel diseasefindings after treatment in predicting the need for surgery (see
further).3. Endoscopy after surgeryECCO Statement 3A
Ileo-colonoscopy is the gold standard in the diagnosis of
post-operative recurrence, by defining the severity of
lesions and predicting the clinical course [EL2]. It is
recommended 6–12 months after surgery where treat-
ment decisions may be affected [EL2] [Voting results:
100% agreement].In the natural history of CD, intestinal resection is un-
avoidable in a significant proportion of patients. A majority
of patients develop disease recurrence at or above the
anastomosis and endoscopic recurrence precedes the devel-
opment of clinical symptoms. Data from endoscopic follow-upof patients after resection of ileo-caecal disease have shown
that in the absence of treatment, the post-operative
recurrence rate is around 65–90% within 12 months and
80–100% within 3 years of the operation.59,60 In another
single centre 15-year retrospective study,61 55 patients
underwent total proctocolectomy with definitive ileostomy
for Crohn's disease. None of them received preventive post-
operative treatment. Probabilities of reoperation for Crohn's
disease recurrence were 0%, 10% and 18% at 1, 5 and 8 years,
respectively. However, symptomatic recurrence after intes-
tinal resection in Crohn's disease is still unpredictable in some
patients.62,63 Identification and treatment of early mucosal
recurrence may therefore prevent clinical recurrence.
Ileocolonoscopy is the gold standard in the diagnosis of post-
operative recurrence by defining the presence and severity of
morphologic recurrence. Ileocolonoscopy is recommended
within the first year after surgery where treatment decisions
may be affected.4. Endoscopy during pregnancy
The safety and utility of endoscopic examinations in the
setting of pregnancy in IBD has not been thoroughly
988 V. Annese et al.evaluated. Nevertheless, small cohort and case controlled
studies indicate that flexible sigmoidoscopy gives a high
diagnostic yield of over 80% when used for an appropriate
indication, such as non haemorrhoidal rectal bleeding and
bloody diarrhoea without significant increase in endoscop-
ic complications for the mother or injury to the foetus
(reviewed in64). Similarly pregnancy and foetal outcomes
in a small study of pregnant patients undergoing colonos-
copy was not different in the second trimester when
compared to matched controls.64 There are no data on the
safety of bowel preparation and sedatives used in pregnant
patients undergoing endoscopic evaluation.645. Endoscopy for differential diagnosis
5.1. Differential diagnosis: CD vs. UC
ECCO Statement 5A
No endoscopic feature is specific for UC or CD. The most
useful endoscopic features of UC are considered to be
continuous and confluent colonic involvement with clear
demarcation of inflammation, and rectal involvement
[EL2]. The most useful endoscopic features in Crohn's
disease are discontinuous lesions, presence of strictures
and fistula and perianal involvement (EL2) [Voting
results: 100% agreement].
While none of the endoscopic features are specific for UC
or CD, in the absence of extra colonic disease, certain
endoscopic findings may suggest a diagnosis of Crohn's colitis
over that of UC. The most prominent of these is the detection
of ‘skip lesions’ of macroscopically and microscopically
uninvolved mucosa. The mucosal features of deep, stellate,
linear, or serpiginous ulcers, multiple aphthous ulcers and
cobblestoning of mucosa are supportive of a diagnosis of
colonic Crohn's disease.50,65–67 In addition, presence of ileitis,
perianal disease or visible fistulous opening is indicative of
Crohn's disease. The pattern of mucosa involvement in UC, in
contrast, is continuous in most cases with a characteristic
sharp demarcation of inflamed and uninvolved colonic
mucosa and the rectum is almost always involved particularly
at index endoscopy.1,22,50,65–69 Strictures are exceedingly
rare in UC and should raise the possibility of CD or underlying
malignancy. The acquisition of the detailed information from
index colonoscopy is important, because once therapy is
started, inflammation often appears segmental, often with
relative rectal sparing.70,71 Patchiness has also been recorded
de novo in paediatric literature.6
There are other pitfalls in the differentiation of UC and
CD. One of these is the concept of backwash ileitis which
typically occurs in up to 20% patients with pancolitis and is
characterised by mild inflammation of a few cms of terminal
ileum without any ulceration.20 Features that favour CD
ileitis include discrete ulcers, strictures of the terminal
ileum or ileocecal valve and absence of pancolitis. In thisscenario additional imaging of the small bowel should be
considered.19,22,68
Upper GI endoscopic lesions suggestive of Crohn's disease
are described in another section. Upper GI endoscopic
findings of focally active gastritis have been described in
Crohn's disease in the absence of Helicobacter pylori72 and in
fact this feature has been incorporated as diagnostic of
upper GI Crohn's in some guidelines.5,9 But it has also been
described in patients with UC as well and thus is little
of help in differentiating the two diagnoses.73 Diffuse
duodenitis in UC has also been reported particularly in
younger patients.74
Endoscopy together with other diagnostic modalities
can differentiate CD from UC in 85% of patients but the
diagnosis may change over time.75 In a prospective study
of more than 350 patients with IBD followed up for more
than 22 months, index colonoscopy and biopsy were
accurate in distinguishing CD from UC in 89% of cases.
IBD diagnosis was revised in 4% of cases and the diagnosis
of indeterminate colitis remained in 7% of cases.76 In a
more recent Scandinavian cohort, 10% of patients had
their diagnosis changed from UC to Crohn's disease or
the diagnosis of inflammatory bowel disease discounted
during the 5 years after initial onset of symptoms.40 IBD
restricted to the colon cannot be allocated to the CD
or UC category in about 5% of cases despite extensive
evaluation and the disease is defined as unclassified
IBD.22,41,685.2. Differential diagnosis: IBD vs. non-IBD colitides
Patients with other colitides can have similar endoscopic
features to those with IBD. The common endoscopic
differential for IBD includes infectious colitis, drug induced
colitis, ischemic colitis, and radiation colitis. Unfortunate-
ly, despite careful history taking and various endoscopic
and histologic findings, it might be difficult in some cases
to distinguish enteric infections from IBD. In a prospective
study investigating patients with acute mucoid bloody
diarrhoea, up to one third were found to have an infectious
aetiology.77 Some of infectious diseases such as Salmonella
spp., Shigella spp. or Campylobacter spp. have endo-
scopic features similar to UC while other infections such
as Yersinia spp. or cytomegalovirus (CMV) enterocolitis
resemble CD. Superimposed infections on IBD due to
Clostridum difficile or CMV can make the situations more
complicated in some instances. While there are no reliable
specific features, some clues on endoscopic appearance
may point towards a non-IBD infective colitis pending
appropriate microbiological testing.78
Several reports have examined colonoscopic findings
related to CMV infection. However, most of these reports
looked at immunocompromised patients such as those
with HIV and post-transplant patients.79–81 The spectrum
of colonoscopic findings in those patients was variable
and ranged from patchy erythema, exudates, and micro-
erosions to diffusely oedematous mucosa, multiple muco-
sal erosions, deep ulcers and pseudotumors.82–87 In
addition, colonoscopic findings of UC complicated by CMV
infection with haemorrhagic appearance of the inflamed
mucosa have rarely been reported.88 It is, however, important
ECCO Statement 6A
Endoscopic evaluation with biopsies from at least one
site is essential in acute severe colitis for diagnosis and
excluding other causes of acute colitis (EL3).
In most cases flexible sigmoidoscopy is sufficient and
colonoscopy and bowel purgatives can usually be
avoided (EL5) [Voting results: 100% agreement].
989European evidence based consensus for endoscopy in inflammatory bowel diseaseto obtain histological confirmation by demonstrating the
typical CMV inclusions.
In endemic areas of tuberculosis, it is not an easy
task to differentiate between CD and intestinal tubercu-
losis endoscopically even after histopathological examina-
tions.89 The majority of TB cases will involve the
ileo-caecal area with varying degrees of contiguous colon
and small bowel involvement. In patients with suspected
or proven CD, ileocolonoscopy provided similar sensitivity
(67% vs. 83%) but significantly higher specificity (100% vs.
53%) compared to video capsule endoscopy in identifying
patients with TB and CD.90 The incremental diagnostic
yield of ileoscopy is reported to be low at 3.7% but this
may be diagnostic in difficult cases.91 Segmental colonic
involvement occurs in 20% of patients in the absence of
ileo-caecal involvement92,93 and skip lesions, may be seen
over 40% of patients.92,94 Approximately 5% may even
mimic pancolitis indistinguishable from UC.95,96 Isolated
small intestinal or upper gastrointestinal tract disease
is also well described.97 A recent systematic analysis
revealed that colonoscopic findings were very useful in
the differential diagnosis of intestinal tuberculosis and
CD.98 In this study, anorectal lesions, longitudinal as well
as aphthous ulcers, and cobblestone appearance were
parameters favouring CD, while localised involvement,
patulous ileocecal valve, transverse ulcers, and scar or
pseudopolyp were parameters favouring intestinal tuber-
culosis. With this method, a positive predictive value for
CD of 94.9% and 88.9% for intestinal TB was achieved. In
a more recent prospective study, skip lesions in the colon
were significantly more frequent in patients with CD
compared to patients with intestinal TB (66% vs. 17%),99
as were aphthous ulceration (54% vs. 13%), linear ulcera-
tion (30% vs. 7%) and superficial ulceration (51% vs. 17%).
Cobblestoning of the colonic mucosa was seen only in
CD (17% vs. 0%). Nodularity of the colonic mucosa
was significantly more common in patients with TB than
in those with CD (49% vs. 24.5%). However, still the
differentiation should be based on epidemiology, clinical
presentation, supportive radiology, histology and immu-
nological assays.100,101
Another differential diagnosis is a well localised inflam-
matory process involving only the sigmoid colonic segment
associated with diverticulosis. This is called segmental
colitis associated with diverticulosis (SCAD), and has
become increasingly recognised as a distinct clinical and
pathological disorder, usually described in older adults,
often presenting with rectal bleeding.102 Recent studies
have confirmed that the incidence of SCAD ranged from
0.3% to 2%.103–105 SCAD has a self-limited clinical course
that resolves without further recurrence or need for
treatment. Because of its similarities to other forms of
inflammatory bowel disease, particularly Crohn's colitis, it
is important to make an accurate diagnosis.106,107 The
endoscopic characteristic of SCAD is that inflammation
is mainly detected within the inter-diverticular mucosa
without involvement of the diverticular orifices. There
is normal mucosa of the rectum and proximal colon.108
SCAD has been further classified endoscopically with four
different patterns.108,109
Ischaemic colitis (IC) is another differential to consider
and may present with typical clinical features mimickingacute presentation of IBD (both UC and CD). Endoscopic
findings that suggest the diagnosis of ischemia include a
normal rectum, sharply defined segments of involvement
particularly of the ‘watershed territory’ from sigmoid
colon to splenic flexure, petechial haemorrhages, lon-
gitudinal ulcerations and rapid resolution on serial exam-
inations.110–114 Because colonoscopy is able to establish the
diagnosis of IC in more than 90% of cases,110 it remains the
diagnostic procedure of choice but it may be risky in the
acute setting and diagnosis can be established by a
sigmoidoscopy with supportive radiology such as abdominal
CT.
Unfortunately, none of the novel endoscopic modali-
ties (i.e. high resolution, digital filtering) have yet been
able to improve the accuracy in differential diagnosis
among IBD and other colitides but this may change in the
future.
6. Endoscopy in acute colitisIf an urgent diagnosis is needed in a patient suspected to
have IBD presenting acutely with bloody diarrhoea, flexibile
sigmoidoscopy with mucosal biopsy is an appropriate initial
investigation.115,116 This will aid in differentiating ulcerative
colitis from other causes of acute colitis.117–119 In one
prospective study of patients presenting with acute hemor-
rhagic colitis-type symptoms, infectious colitis was found to
be the cause in 38% of the cases.77 However, stool cultures
are positive in only 40%–60% of cases, so a negative stool
culture does not rule out infection120 and hence endoscopy
can be a useful adjunct to microbiological tests in these
patients.121 In addition, endoscopic appearances on treat-
ment naive colon in the acute setting may be helpful in
determining the pattern of inflammation pointing towards
ulcerative colitis or Crohn's.122
In established cases of IBD, endoscopy during an acute flare
is an important tool in determining the severity of the disease
flare.123,124 There is poor correlation between clinical and
endoscopic indices of severity during acute colitis flare both in
ulcerative colitis and in Crohn's disease.125–128 However, the
presence of extensive and deep ulcerations at endoscopy
is associated with an increased risk of colectomy for UC
in that admission.128–133 In addition endoscopy can be useful in
predication of response to rescue therapy using cyclospor-
ine134 or infliximab.135 In an established patient with IBD,
co-existent enteric infections account for a significant
proportion of flares136,137 and in these patients sigmoidoscopy
can be a useful adjunct to indicate superadded infections such
ECCO Statement 8A
Endoscopic dilatation of strictures in Crohn's disease
is a safe and effective alternative to surgery in
experienced hands and should be considered before
surgery in selected patients [EL2]. The best outcomes
are obtained in short strictures (b4 cm) and anasto-
motic strictures (EL2). The possibility of a malignant
stricture must be ruled out [EL3] [Voting results: 100%
990 V. Annese et al.as CMV by detecting specific inclusions and in C. difficile
by demonstrating pseudomembranes. However, pseudo
membranes may be absent in IBD patients with C. difficile
infection.70,138,139 The data on the safety of sigmoidoscopy
and colonoscopy during the acute phase of colitis is
scarse.71,115,130 Most patients will only need a flexible
sigmoidoscopy and colonoscopy may be potentially harm-
ful.140 Similarly it is advised that purgatives, especially
fleet enemas and oral sodium phosphate preparations
should be avoided in this setting.117
7. Endoscopy of ileoanal pouchECCO Statement 7A
Endoscopy with biopsies should be performed in the
assessment of pouch-related symptoms (EL3) [Voting
results: 100% agreement].
agreement] [Voting results: 100% agreement].Although ileal pouch–anal anastomosis (IPPA) in UC pa-
tients improve patients health related quality of life,
inflammatory, non-inflammatory complications and sequel-
ae are common with frequency of pouch failure up to 7%
at 3 years and 9% at 5 years.141,142 Endoscopy plays a
significant role in diagnosing and guiding therapy in such
patients.143–147 Pouchitis occurs in 23–46% of patients
following IPPA142 and is a heterogeneous entity with no
specific symptoms and signs. In addition, the severity of
symptoms does not always correlate with the endoscopic or
histological findings.148,149 Therefore a cumulative clinical,
endoscopic and histological assessment is needed. Several
diagnostic criteria are available and the commonest in
clinical use is the pouch disease activity index.150 Further-
more, it is valuable to classify the phenotype of pouchitis
before initiating therapy to provide guidance as to
treatment modalities and duration of treatment.151–153 In
case of antibiotic refractory pouchitis, endoscopic evalua-
tion can aid in excluding contributory factors such as
ischemic pouchitis and infections.154,155
Pouch endoscopy is essential in the diagnosis of Crohn's
disease of the pouch.156 However, endoscopic appearances
are not specific particularly in de novo CD.157
Endoscopic balloon dilatation can be used for therapy of
stricture of the pouch in experienced hands.157,158
Another indication for pouch endoscopy is surveillance
of dysplasia. There is a small risk of carcinomas (b5%)
arising in the pouch which can present as flat or polypoid
lesions.159–162 In a systematic review, the prevalence of
dysplasia in the rectal cuff and pouch was found to be
similar indicating that surveillance should be identical
in these 2 groups.163 Annual surveillance pouchoscopy
is recommended in patients with high risk features such
as associated PSC, atrophic pouch mucosa, ileal pouch-
rectal anastomosis and presence of dysplasia in the
original colectomy specimen.92,164–166 In selected patients
with pouch problems upper gastrointestinal endoscopy can
yield valuable information for differential diagnosis.938. Therapeutic endoscopyIntestinal strictures are a major cause for morbidity
and need for surgery in Crohn's disease. Traditional treat-
ment involved surgical resection and stricturoplasty but
there is a high rate of recurrence needing reoperation.94,167
Over the last 15 years there is increasing evidence for
endoscopic balloon dilatation as a safe and effective
alternative to surgery, particularly of ileocecal and anas-
tomotic strictures.168–192 However these studies are all
mainly retrospective with observational study design, and
while few studies are prospective with long term follow
up171,173,176,184,185,187,190,192 controlled studies are lacking.
The technical success for endoscopic balloon dilatation is
reported to vary between 86 and 93% in different series, and
the clinical success (defined as resolution of obstructive
symptoms) is 64–70%, increasing to 78% when patients with
failed procedures due to technical reasons are excluded.168
On long term follow up studies, the cumulative proportion of
patients needing surgery at 1, 3 and 5 years vary form
13–17%, 28–42%, and 36–42% respectively. Strictures recur
following dilatations and re-dilatations may be required
in up to 20% of patients at 1 year and up to 50% by
5 years.170,171,173,178,183,186 These are comparable to recur-
rence rates following stricturoplasty of 45% at 5 years.191
Balloon dilatation has also been used successfully in
gastro-duodenal strictures although the numbers of reported
cases are small.193–195 Best results in terms of surgery free
outcome are obtained when stricture length is b4 cm and for
anastomotic strictures when compared to de novo stric-
tures.168,181,184,186 Influence of other factors on success such
as concurrent medical therapy, smoking status and disease
activity status is currently uncertain.196–198 Most dilatations
can be performed without anaesthetic using conscious
sedation.
Major complications, including bowel perforation and
significant bleeding, occurs in about 2% of patients.168 This
is probably acceptable in comparison to the stricturoplasty
havingmajor complication rates of over 5%.193 There is data to
suggest balloon diameters of 25 mm have increased risk of
complications.179,186 So far no mortality past balloon dilata-
tion has been reported. Intra-lesional steroids199–203 and
Infliximab204 to prolong the results of endoscopic dilatation
have been attempted in some studies with variable results. In
a small randomised placebo controlled trial of paediatric
Crohn's patients,203 intralesional steroids reduced the need for
re-dilatation and recurrence surgery, but this has not been
confirmed in the only randomised pilot study in adults.199
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and dilation of ileal pouch strictures158 are reported to be
successful in expert hands. Since there are no randomised
studies comparing stricturoplasty and dilatation, the decision
on individual patients should be based on stricture length,
patient preference and the available expertise. The use of
metallic and biodegradable stents209,210 in the setting of
Crohn's disease strictures needs further studies.
9. Endoscopic activity in IBD
9.1. Ulcerative colitis scoring systemsECCO Statement 9A
Instruments for measuring endoscopic disease activity
in UC are available, but in daily routine such indices are
barely used.
The ulcerative colitis endoscopic index of severity
(UCEIS) and the ulcerative colitis colonoscopic index of
severity (UCCIS) received formal validation [EL2]. Sev-
eral other endoscopic scoring systems for disease
severity are available and commonly used, albeit lacking
formal validation [EL5] [Voting results: 86% agreement].
The Mayo score has been extensively used in
randomised controlled trials to assess endoscopic
response. Endoscopic remission has been defined as a
Mayo subscore ≤ 1 [EL1], however complete endoscop-
ic remission should be restricted only to score 0
(normal or completely healed mucosa) [EL2] [Voting
results: 100% agreement].The first attempt to classify endoscopic ulcerative colitis
(UC) severity was made by Truelove and Witts back in 1955
during a placebo-controlled trial evaluating cortisone for the
treatment of active UC.211 Mucosal appearance was classi-
fied into three categories: (1) normal or near normal (slight
hyperaemia or slight granularity), (2) improved, or (3) no
change or worse. However, this classification lacks well-
defined endoscopic descriptors.
A decade later, in 1964, Baron et al. evaluated the
inter-observer agreement in describing the mucosal appear-
ance of 60 patients with UC using rigid sigmoidoscopy.212 The
degree of disease activity was based on a 4-point scale (0–3)
according mainly to the severity of bleeding. Mucosal
friability, described as bleeding to light touch of the mucosa
was pivotal in discriminating between mild and moderately
active disease. Of note, the presence of ulceration was not
taken into account when defining the severity of mucosal
inflammation. A Baron score ≤1 (0: normal mucosa; 1:
abnormal mucosa but non-haemorrhagic) was defined as
endoscopic remission. Remarkably, after more than four
decades since the Baron score was first described, it has still
not been formally validated.
The Powell-Tuck213 index, known as the St. Mark's index,
also graded the severity of inflammation using a 3-point
scale (0–2) focusing on mucosal bleeding as the predominantvariable (non-haemorrhagic mucosa, bleeding on light
touch, and spontaneous bleeding).
The Sutherland index (UC-Disease Activity Index;
UC-DAI)214 was developed during a placebo-controlled
trial evaluating the efficacy of mesalamine enemas for
the treatment of distal UC. The mucosal appearance was
described on a 4-point scale (0–3) evaluating three
endoscopic findings: (1) friability, (2) exudation, and
(3) spontaneous haemorrhage.
The endoscopic component of the Mayo score215 was
developed in 1987 by Schroeder et al. during a placebo-
controlled trial evaluating the efficacy of an oral delayed
release mesalamine for the treatment of active UC. The
degree of endoscopic rectal inflammation was based on a
4-point scale (0–3) according to the following findings:
(0) normal, (1) erythema, decreased vascular pattern, mild
friability, (2) marked erythema, absent vascular pattern,
friability, erosions, and (3) ulceration, spontaneous bleeding.
The Mayo endoscopic subscore is the most commonly used
in clinical trials for the evaluation of treatment efficacy
in terms of endoscopic remission. Mucosal healing has
been defined as a subscore of 0–1.216 However, some
studies have used a more strict definition of complete
mucosal healing as Mayo endoscopic subscore of 0.217
Nevertheless, these definitions have not been properly
validated, and the current recommendation of the Food and
Drug Administration (FDA) is to consider any friability as non-
healed mucosa.
The Rachmilewitz endoscopic index218 was developed
during a controlled trial comparing a coated mesalamine
with sulfasalazine for the treatment of active UC. The index
included four variables: (1) vascular pattern, (2) granularity,
(3) mucosal damage (mucus, fibrin, exudate, erosions,
ulcers), and (4) bleeding. Scores range from 0 to 12 points,
the cut-off for defining endoscopic remission being ≤4
points.
In 2005, in a placebo-controlled trial of a humanised
antibody to the α4β7 integrin (MNL02), Feagan et al.
described the modified Baron score.36 Endoscopic activity
was categorised on a 5-point scale (0–4) taking into account
the following variables: vascular pattern, granularity,
hyperaemia, friability, ulceration, and bleeding. Endoscopic
response was defined as an improvement of at least 2 points
from baseline. Endoscopic remission was defined as a score
of 0 points (normal mucosa, with a visible vascular pattern
and no friability).
None of the above listed indices and the definitions
of endoscopic response/remission have been properly
validated.
In an attempt to construct and validate a reliable
instrument to measure endoscopic severity in UC, Travis
et al. derived a new tool, the Ulcerative Colitis Endoscopic
Index of Severity (UCEIS), based on the intra- and inter-
individual variability of 10 endoscopic descriptors.34 This
new index grades three endoscopic findings, (1) vascular
pattern, (2) bleeding, and (3) erosions/ulcers, each of them
with precise definitions, on three to four levels, capturing
90% of the variance in the overall assessment of endoscopic
severity. A notable finding is that friability has been
excluded from the index. Validation of remission and
severity is still in progress as well as the operating properties
of the index (responsiveness and reliability)37 . Once further
992 V. Annese et al.validated, the UCEIS will be available for clinical trials
bringing consistency to endoscopic assessment of disease
severity in UC.
More recently Samuel S et al. prospectively validated
a further index named Ulcerative Colitis Colonscopic Index of
Severity (UCCIS).219 The index includes six variables: (1) vascular
pattern, (2) granularity, (3) ulceration, (4) bleeding/friability,
(5) grading of segmental and global assessment of endoscopicTable 9.1 Comparison of Endoscopic Scoring indexes in Ulcer
Severity, UCCIS: Ulcerative Colitis Colonscopic Index of Severi
Score Endoscopic variables Strengths
Truelove and Witts
Sigmoidoscopic
assessment211
Lack of endoscopic
descriptors definitions
–
Baron Score212 Vascular pattern,
friability, bleeding
Easy to calcu
Powell-Tuck index
(St. Mark's Index)213
Bleeding
(non-haemorrhagic vs.
haemorrhagic mucosa)
–
Sutherland Index214 Friability, exudation,
spontaneous
haemorrhage
–
Mayo Endoscopic
Subscore215
Erythema, vascular
pattern, friability,
erosions, ulcers,
bleeding
Easy to calcu
used in clinic
Rachmilewitz Index218 Vascular pattern,
granularity, mucosal
damage (mucus, fibrin,
exudate, erosions,
ulcers, bleeding
Easy to calcu
Modified Baron Score36 Vascular pattern,
granularity,
hyperaemia, friability,
ulceration, bleeding
Easy to calcu
clinical trials
UCEIS34 Vascular pattern,
bleeding, erosions/
ulcers,
Accurate for
assessment o
severity Deve
following rigo
methodology
undergoing in
validation
(responsiven
reliability)
UCCIS220 Vascular pattern,
granularity, ulceration,
bleeding/friability
Accurate, ea
scored as bas
only four diff
parameters D
validated fol
rigorous met
Covers the eseverity with a predefined 4-point scale, and (6) global
assessment of endoscopic severity on a 10-cm VAS scale.
Interobserver agreement was good to excellent for the 4
mucosal lesions evaluated. A significant correlation with
clinical activity and some biomarkers (i.e. C reactive protein)
was also demonstrated, but a definition of a cut off level
for endoscopic response and remission is still lacking
(Table 9.1).ative Colitis (UCEIS: Ulcerative Colitis Endoscopic Index of
ty).
Weaknesses Proposed remission
score
– –
late Do not evaluate ulcers
Subjective interpretation
of friability and bleeding
Poor inter-observer
agreement
0–1
Only evaluates bleeding
Subjective interpretation
Not defined
Do not evaluate ulcers Not
accurate to discriminate
between mild to moderate
friability
0
late Widely
al trials
Not accurate to
discriminate between mild
to moderate friability
0–1
late Subjective interpretation
of mucosal damage and
bleeding
0–4
late used in No discrimination between
superficial and deep
ulceration
0
the
f disease
loped
rous
Currently
dependent
ess,
Low agreement for normal
appearance of the mucosa
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ntire colon
Single center
development, high
expertise: larger
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ECCO Statements 9B
The severity of post-surgical Crohn's disease recurrence
in the neo-terminal ileum should be classified according
to Rutgeerts' score [EL3] [Voting results: 93% agreement].
The Crohn's disease endoscopic index of severity
(CDEIS) [EL1] and the simple endoscopic score for
Crohn's disease (SES-CD) [EL1] are validated and
reproducible scoring systems dedicated to luminal
Crohn's disease endoscopic activity measurement, but
their use in routine clinical setting has still to be
determined. [EL5] [Voting results: 100% agreement].
There is no validated definition of mucosal healing in
Crohn's disease. Reporting of endoscopic activity should
include accurate descriptions of any abnormalities in
each segment, and whenever possible according to
validated indices [EL5] [Voting Results: 100% agreement].In the post-surgical setting measurement of activity rele-
vant to clinical and surgical recurrence at the site of ileo-
colonic anastomosis can be recorded using the Rutgeerts'
score for post-surgical recurrence. The score was developed
and validated in order to predict a relevant difference inTable 9.2 Most commonly used endoscopic scores for CD (CDEIS
endoscopic score for Crohn's disease).
Score Variables included Field of app
Rutgeerts'
score59,60
Aphtous ulcers, ulcers, aphtoid ileitis,
erythema, cobblestone, stenosis (all to
be evaluated at the anastomotic site or
in the afferent ileal limb of an
ileocolonic anastomosis)
Postoperati
at the site o
anastomosis
other surge
CDEIS225 Superficial ulcers, deep ulcers, surface
affected by ulcers, surface affected by
disease, ulcerated stenosis,
non-ulcerated stenosis (all to be scored
in all ileocolonic segments explored)
Luminal Cro
to measure
endoscopic
mucosal he
SES-CD226 Ulcer size, surface affected by ulcers,
surface affected by disease, type of
bowel narrowing (all to be scored in all
ileocolonic segments explored)
Luminal Cro
to measure
endoscopic
mucosal heprognosis in the post-surgical setting.59,60 Although the
score lacks formal evaluation of inter-observer agreement,
it has been widely used across many different clinical trials
and clinical series and its prognostic value was confirmed in
clinical trials over the past 20 years.220–224 More specifical-
ly, patients with recurrence graded i2 or more were shown
to present with a more severe course of disease in terms of
clinical and surgical recurrence, while patients with no (i1) or
minimal (i1, e.g. less than 5 aphtous recurrent lesions with
normal mucosa interposed) endoscopic recurrence are at
minimal risk of subsequent recurrence.
In the setting of luminal Crohn's disease, endoscopic
activity may reliably be scored with one of the validated
endoscopic activity scores, either being the Crohn's disease
endoscopic index of severity (CDEIS)225 or the simple
endoscopic score for Crohn's disease (SES-CD).226 Both scores
were shown to be highly reproducible (with excellent inter-
observer agreement demonstrated) and they were prospec-
tively validated.225–228 Nonetheless both scores are rather
complicated, and therefore their use is restricted to clinical
trials at present and not often used in routine clinical
practice. However, reporting of endoscopic activity should
always include accurate descriptions of any abnormalities in
each segment.
The CDEIS was developed225 through a selection process
involving all endoscopic features of Crohn's disease, then
restricting the observation to those with best inter-observer
agreement, weighting individual endoscopic variables (by: Crohn's disease endoscopic index of severity, SES-CD: Simple
licability Strengths and weaknesses
ve recurrence (only
f an ileo-cecal
, not suitable for
ries)
Strengths:
Well known and widely accepted, easy
and suitable for routine practice,
relevant prognostic value
Weaknesses:
Potential agreement issues, no formal
validation of the score
hn's disease, useful
variations of
activity (including
aling)
Strengths:
Validated and used in several trials,
sensitive to variations in endoscopic
activity, allows comparison of different
endoscopic examination, prognostic
relevance demonstrated
Weaknesses:
Complex, requires post-procedure time to
be scored, not suitable for routine practice
hn's disease, useful
variations of
activity (including
aling)
Strengths:
Validated and used in several trials,
sensitive to variations in endoscopic
activity, allows comparison of different
endoscopic examinations, prognostic
relevance demonstrated, simplification
of some CDEIS variables, results may be
linearly derived into CDEIS values
Weaknesses:
Still complex, requires post-procedure
time to be scored, not suitable for
routine practice
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of lesion severity (GELS) scored on a visual-analogue scale by
different clinicians observing the same endoscopic pictures.
The final score takes into account whether a given segment
is explored/available or not, lesions with different relevance
(deep/superficial ulcers), surface of colon affected by Crohn's
lesions and by ulcers in particular, and finally presence or
absence of ulcerated or non-ulcerated narrowing. At least one
of the variables, the presence of deep colonic ulcers, is an
independent driver of severe prognosis, with patients affected
by deep ulcers displaying significant higher rates of
colectomies and of new draining fistulae during the long-term
follow-up compared to those patients without deep ulcers.229
The SES-CD was developed226 aiming to correlate at best
with CDEIS, through a simplification process of the endo-
scopic variables, which were reduced to hierarchical and
categorical and restricted to presence and size of ulcers,Table 9.3 Characteristics of the most commonly used scores for
SES-CD: Simple endoscopic score for Crohn's disease).
Score Applicability Variable Gradi
Mayo
endoscopic
subscore
UC Mayo 0 Norm
Mayo 1 Faded
Mayo 2 Absen
Mayo 3 Spont
Rutgeerts'
score
Post-operative
CD
i0 No les
i1 ≤5 af
i2 N5 af
larger
anast
i3 Diffus
i4 Diffus
CDEIS Luminal CD Deep ulcers (in all explored
segments)
Absen
Prese
Superficial ulcers (in all
explored segments)
Absen
Prese
Surface involved by disease
(in all explored segments)
0–10
repre
Surface involved by ulcers
(in all explored segments)
0–10
repre
Ulcerated stenosis
(anywhere)
Absen
Prese
Non-ulcerated stenosis
(anywhere)
Absen
Prese
SES-CD Luminal CD Ulcers (in all explored
segments)
Absen
Aphto
Large
Very l
Ulcerated surface (in all
explored segments)
None
b10%
10–30
N30%
Affected surface (in all
explored segments)
None
b50%
50–75
N75%
Narrowings (in all explored
segments)
None
Single
Multip
Not pamount of the surface affected by ulcers or by any Crohn's
lesion and presence/type of narrowing of the bowel lumen.
It was shown to have a close correlation, which enables users
to convert SES-CD results into CDEIS and vice-versa using a
straight-forward equation: CDEIS = 0.76 ∗ SES-CD + 0.29.
During the past few years, there were attempts to define
endoscopic remission or minimal activity according to possible
CDEIS (lower than 3 points)230,231 or SES-CD (lower than 5
points)232 cut-off values, although the best prognosis seemed
to be associated to CDEIS or SES-CD scores of 0 points.231,233 A
recently published review outlined the absence of accepted
and shared definitions of endoscopic healing.234 A different
endoscopic activity scale, which should be used both for
Crohn's disease and ulcerative colitis, is the operative one used
in IBSEN study235: this score ranges between 0 and 2 points (0 =
normal; 1 = light erythema or granularity; 2 = granularity,
friability, and bleeding, with or without the addition ofUC and CD (CDEIS: Crohn's disease endoscopic index of severity,
ng
al or healed mucosa
vascular pattern, mild friability, erythema
ce of vascular pattern, marked friability, erosions
aneous bleeding, large ulcers
ions in neoterminal ileum
toid ulcers
toid ulcers with normal mucosa in-between, or skip areas with
lesions, or lesions/ulcers (b1 cm) confined to ileocolonic
omosis
e aftous ileitis with extensively inflamed mucosa
e inflammation with large ulcers, nodules and/or stenosis
t (0 points)
nt (12 points)
t (0 points)
nt (6 points)
(as the result of visuoanalogic scale transformation
senting a complete ileocolonic segment)
(as the result of visuoanalogic scale transformation
senting a complete ileocolonic segment)
t (0 points)
nt (3 points)
t (0 points)
nt (3 points)
t (0 points)
us ulcers, 0.1–0.5 cm (1 point)
ulcers, 0.5–2 cm (2 points)
arge ulcers, N2 cm (3 points)
(0 points)
of the segment (1 point)
% of the segment (2 points)
of the segment (3 points)
(0 points)
of the segment (1 point)
% of the segment (2 points)
of the segment (3 points)
(0 points)
, passable by endoscope (1 point)
le, passable by endoscope (2 points)
assable, frank stenosis (3 points)
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while all types of ulceration (or of active inflammation) were
linked to a score of 2 (“not healed”), both in ulcerative colitis
or Crohn's disease patients (Tables 9.2 and 9.3).
10. Endoscopic severity and prognosis
10.1. Endoscopic activity and prognosis in UCECCO Statement 10A
Mucosal healing in ulcerative colitis is associated with
lower risk of clinical relapse, hospitalisation and
colectomy and with lower risk of colitis associated
neoplasia [EL2] [Voting Results: 100% agreement].
Mucosal healing is presently assessed with white light
endoscopy; this evaluation may be augmented with
specific magnified techniques, and may refine progno-
sis [EL2] [Voting Results: 86% agreement].Treatment for ulcerative colitis is increasingly directed, as
in Crohn's disease, towards mucosal healing as this end point
seems to offer better prognosis compared to symptomatic
control alone. In a clinical trial setting, “Mucosal healing”
can vary from: light erythema, granularity and or friabili-
ty47,235 to more stringent definitions: normal mucosal with
the absence of all ulceration, both microscopic and
macroscopic, providing a sigmoidoscopy score of 0 with no
friability.214ECCO Statements 10B
In the absence of a formally validated definition,mucosal
healing could be defined either as the absence ofmucosal
ulceration, or a Crohn's disease endoscopic index of
severity (CDEIS) score of 0, or a simple endoscopic score
for Crohn's disease (SES-CD) of 0 [EL3] [Voting Results:
100% agreement].
Achieving mucosal healing with Crohn's disease therapy
is associated with a short-term decrease in relapse and
hospitalisation rates and the need for surgery [EL2]
[Voting Results: 100% agreement].
Early post-operative endoscopic recurrence (Rutgeerts'
score ≥ i2) is associated with a higher symptomatic
and surgical recurrence rates [EL1]. Therefore medical
adaptation should be considered [EL2] [Voting Results:
100% agreement].10.1.1. Endoscopy in predicting outcomes
Endoscopic “mucosal healing” was associated with a lower
risk of colectomy at one year in a combined analysis of the
ACT 1 and 2 studies in patients who had achieved mucosal
healing with infliximab at week 8 (95% colectomy free for
Mayo sub score 0–1, 80% for 3, p = 0.004).47 The IBSEN
cohort from the pre-biological therapy era demonstrated
patients with mucosal healing at one year had a lower risk of
colectomy at 5 years (risk ratio 0.22, p = 0.02).235 Mucosal
healing defined as Baron score of 0 was associated with
lower risks of hospitalisation, colectomy and subsequent
immunosuppressive use.236 Endoscopic “normal colonic
appearance” was associated with a lower risk of colitis
related neoplasia (odds ratio 0.38, p = 0.003), with a cancer
risk in those with a normal “healed” colon that was not
different to population risk.237 The prognostic importance
of mucosal healing, first suggested by Wight and Truelove in
1966211,238 seems to be independent of the means to
achieve it, being seen in patients treated with or without
biological therapies. Increasing colonoscopic inflammation
was correlated with the risk of colitis associated neoplasia
during surveillance in a univariate analysis, odd ratio 2.5,
p = 0.001.239 Severe lesions, defined as “extensive deep
ulcerations, mucosal detachment at the edge of ulcers,
well-like ulcers and large mucosal abrasions”, were associ-
ated with failure of intensive intravenous treatment with
steroids (relative risk 2.32, p = 0.007) and the risk ofsubsequent colectomy during follow up.130,132 In a large
multi-centre series of patients with acute severe colitis who
received cyclosporine as rescue therapy, severe lesions
were strongly associated with subsequent colectomy by
6 months (73% versus 42%, p b 0.01).134 Patients with at
least one segment of severe inflammation were more likely
to have colonic neoplasia during colonoscopic surveillance
in a univariate analysis, odds ratio 3.38, p = 0.008.237
10.1.2. Endoscopic severity and QoL
Endoscopic inflammation score (according to Rachmilewitz)
had a negative correlation with quality of life (QoL), measured
with the inflammatory bowel disease questionnaire, with
higher (worse) endoscopic scores having lower QoL, r = 0.51,
p = 0.005.240 A similar relationship between Mayo endoscopic
sub score and QoL measurement was seen in the ACT 1 and 2
studies r = 0.50, p b 0.001.241
10.1.3. Advanced endoscopy in UC and prognosis
Apparently normal mucosa at endoscopy can be sub-classified
by advanced endoscopic imaging techniques. In a prospective
study of patients who had achieved clinical and endoscopic
remission, crypt opening abnormalities seen with magnifying
chromoendoscopy were associated with relapse over
12 months.242 Recently in another mixed cohort of patients
with inflammatory bowel disease in clinical remission with
normal mucosa, local barrier dysfunction as assessed
by confocal endomicroscopy (cell shedding, microerosions
and fluorescein leakage) was associated with a higher risk of
relapse.243
Although endoscopic severity is associated with worse
outcomes, there is as yet no evidence that targeting
endoscopic mucosal healing as a treatment outcome will
result in better patient outcomes in the short and long term
in ulcerative colitis. There remains a need to clearly define
endoscopic criteria for both mucosal healing and severe
endoscopic lesions.
10.2. Endoscopic activity and prognosis in
Crohn's disease
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An increasing body of evidence suggests that mucosal
healing (MH) may change the natural course of CD by
decreasing relapse rates, hospitalisation rates and the need
for surgery. Unfortunately, a wide variation of definitions of
MH has been used in different clinical trials, some evaluating
the absence of mucosal ulcerations, others using validated
endoscopic activity scores such as the Crohn's disease
endoscopic index of severity (CDEIS) or the simple endo-
scopic score for Crohn's disease (SES-CD).225,226
In a single centre cohort study published in 2002, the
presence of deep ulcerations at index colonoscopy indepen-
dently predicted a more aggressive disease course including
the development of new fistulae and increased colectomy
rates throughout follow-up (risk ratio 5.43).229 A similar finding
was observed in the IBSEN cohort, a Norwegian population-
based cohort study including CD patients who underwent index
ileocolonoscopy one year after initiation of CD therapy. During
follow-up, patients achieving MH (absence of marked granu-
larity and friability, absence of bleeding and ulcerations) one
year after initiation of CD therapy showed a trend towards
lower surgical resection rates compared to patients not
achieving MH (12% vs. 22%, p = 0.010).235 In a 10-year
extension of this study, the risk of surgery was significantly
reduced among patients who achieved MH compared to
patients who did not achieve MH one year after initiation of
CD therapy (hazard ratio 0.42).244,245
Sub-studies of ACCENT-1 showed that patients who
achieved MH (absence of mucosal ulcerations) with infliximab
(IFX) had a longer relapse-free survival and required fewer
disease-related hospitalisations and surgeries compared to
those who did not achieve MH.246–248 In a sub-study of the
SONIC trial, patients achieving MH (absence of mucosal
ulcerations) at week 26 were more likely to maintain steroid-
free clinical remission (SFCR) at week 50 compared to patients
not achieving MH (76% vs. 58%).249,250 The highest rate for
SFCR at week 50 (82%) was achieved among patients with both
MH and SFCR at week 26. In a sub-study of the EXTEND trial,
achievement of early deep remission (absence of ulcerations
and CDAI b 150) 12 weeks after initiation of adalimumab
(ADA) therapy was significantly associated with a better
quality of life at week 52 and showed a trend towards lower
CD related hospitalisation and surgery rates.49,251
Also, the long-term follow-up of the step-up/top-down
trial showed that, when combining the two treatment arms,
patients achieving MH (SES-CD = 0) at year two more
frequently remained in SFCR during the following two years
compared to patients with persistent endoscopic activity at
year two (71% vs. 27%, respectively, p = 0.003).233,252
Currently, it's not clear what degree of MH is required to
avoid disease progression and to change the natural disease
course. In a retrospective single centre cohort study
reporting the long-term outcome of IFX in 214 patients
with CD with a median follow-up of 69 months, patients
achieving complete MH (absence of mucosal ulcerations)
more frequently experienced a sustained clinical benefit
compared to patients who did not achieve MH (64.8% vs.
39.5%, p = 0.0004).252,253 Furthermore, fewer disease-related
hospitalisations (42.2% vs. 59.3%, p = 0.0018) and a lower
need for major abdominal surgery (14.1% vs. 38.4%,
p b 0.0001) was observed in the group who achieved MH.
Interestingly, major abdominal surgery rates were notsignificantly different between patients achieving complete
and partial MH, the latter defined as clear endoscopic
improvement (14.1% vs. 14.0%). Several investigators have
tried to define a minimal degree of endoscopic improvement
(endoscopic response) which is clinically relevant for improv-
ing the long-term outcome, but until now the proposed cut-off
values in CDEIS and SES-CD have not been validated.254,255
In a placebo-controlled study by the GETAID including 83
patients in clinical remission under azathioprine (AZA), neither
presence of ulcerations nor a CDEIS N 0 at ileocolonoscopy
before discontinuation of AZA were predictive for clinical
relapse.256 In contrast, in another recent GETAID trial, Louis et
al. assessed the risk of clinical relapse after discontinuation of
IFX in 109 patients with CDwhowere in clinical remission under
a combined maintenance therapy with IFX and an immuno-
modulator.231 In their multivariate analysis, the absence of MH
(CDEIS N 0) was among the factors strongly associated with an
increased risk of clinical relapse after IFX withdrawal (hazard
ratio 2.6). In this study, immunosuppression with AZA or
methotrexate was continued after IFX withdrawal.
Finally, within the first year after an ileocolonic resection
for CD, the presence of endoscopic lesions at the anastomo-
sis or in the neo-terminal ileum during endoscopy predict
postoperative clinical recurrence.60 Throughout follow-up,
symptomatic recurrence occurred less frequently in patients
who had no severe endoscopic lesions at one year (Rutgeerts'
score i0 or i1) compared to patients with a more severe
endoscopic recurrence (Rutgeerts' score ≥ i2).
11. Small bowel endoscopy
11.1. Small bowel capsule endoscopy (SBCE) in
patients with suspected Crohn's disease
ECCO Statement 11A
In patients with suspected Crohn's disease and negative
ileocolonoscopy, small bowel capsule endoscopy may
be the initial diagnostic modality for the evaluation of
the small bowel, in the absence of obstructive
symptoms or known stenosis. In patients with obstruc-
tive features or known stenosis, a cross-sectional
imaging modality such as MR enterography or CT
enterography should be the method of choice [EL2]
[Voting results: 93% agreement].
Crohn's disease frequently involves the terminal ileum,
which is accessible to conventional endoscopic evaluation
and biopsy at the time of ileocolonoscopy. However, in some
patients, Crohn's disease may affect the proximal small
bowel out of reach of the colonoscope or terminal ileum
intubation may be unsuccessful.22 In this setting, the
diagnostic yield of the capsule for small bowel lesions is
higher than ileocolonoscopy, small bowel follow-through and
CT enterography.2,257 Moreover, SBCE may also be superior
to MR enterography (MRE), particularly for early mucosal
lesions and for proximal small bowel lesions.258–260 Dionisio
et al.257 conducted a meta-analysis evaluating the diagnostic
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small bowel follow-through or enteroclysis (SBE/SBFT),
computed tomography enterography or enteroclysis (CTE)
and MRE. Data on patients with suspected and established
Crohn's disease were independently analyzed. A total of 12
trials (n = 428 patients) compared SBCE with SBE/SBFT, eight
trials (n = 236) compared SBCE with ileocolonoscopy, four
trials (n = 119) compared SBCE with CTE, two trials (n = 102)
compared SBCE with PE, and four trials (n = 123) compared
SBCE with MRE. In this meta-analysis, SBCE was superior to
SBE/SBFT, CTE and ileocolonoscopy, with significant weighted
incremental yield (IY) in the evaluation of patients with
suspected Crohn's disease (SBCE versus SBE/SBFT: 52% versus
16% [IY = 32%, P b 0.0001, 95% CI = 16–48%], SBCE versus
CTE: 68% versus 21% [IY = 47%, P b 0.00001, 95% CI = 31–
63%], and SBCE versus ileocolonoscopy: 47% versus 25% [IY =
22%, P = 0.009, 95% CI = 5–39%]. No significant IY was
observed when SBCE was compared to MRE: 55% versus 45%
(IY = 10%, P = 0.43, 95% CI = −14–34%). Recently, Jensen
et al.258 published the results of a prospective, blinded study
of multiple small-bowel imaging modalities, comparing SBCE,
CTE and MRE performed after ileocolonoscopy in 93 patients
with suspected or established Crohn's disease. The sensitivity
and specificity for terminal ileum Crohn's disease were 100%
and 91% for SBCE, 76% and 85% for CTE, and 81% and 86% for
MRE, respectively, while the capsule significantly enhanced
the detection of small bowel lesions proximal to the terminal
ileum.
Crohn's disease begins with a mucosal inflammatory
pattern that over time develops into strictures or fistulas.8,9
Timely diagnosis and early treatment may lead to better
outcomes.253,261 SBCE has the potential to assume a central
role in the early diagnosis of patients with suspected Crohn's
disease, as it is the most sensitive diagnostic test to detect
early small bowel lesions. In addition, due to the high negative
predictive values of a normal examination being consistently
reported, small bowel Crohn's disease can possibly be
excluded inmost patients with a negative capsule study.262,263
11.2. Diagnostic accuracyECCO Statement 11B
Small bowel capsule endoscopy has a high negative
predictive value for small bowel Crohn's disease [EL 4]
[Voting results: 100% agreement].
ECCO Statement 11D
The pre-test probability of detecting Crohn's disease by
small bowel capsule endoscopy can be enhanced by
selection of patients based on additional features
beyond symptoms, such as typical extraintestinalECCO Statement 11C
Endoscopic differentiation of small bowel Crohn's disease
from drug-induced lesions or other diseases is unreliable
[EL3]. Non-steroidal anti-inflammatory drugs (NSAIDs)
should be withdrawn at least four weeks prior to small
bowel capsule endoscopy in the setting of suspected
Crohn's disease [EL4] [Voting results: 100% agreement].The specificity of minor mucosal lesions on SBCE in suspected
Crohn's disease has been debated.2,264 Indeed, higher diag-
nostic yield may not correspond to higher diagnostic accuracy,
as the small lesions detected by the capsule may not be
specific for Crohn's disease as such lesions may be found in a
number of other conditions,265 such as in Behçet's disease,
vasculitis, or drug-induced enteropathy, particularly due to
non-steroidal anti-inflammatory drugs (NSAIDs).266–270 More-
over, SBCE has been shown to detect minor mucosal breaks
and erosions in about 10% of healthy individuals.271 In a cohort
of 102 patients with suspected Crohn's disease, 37% were
initially diagnosed with small bowel ulcerations in SBCE but
only in 13% was the diagnosis of Crohn's disease confirmed at
one year follow up.272 In a former prospective study comparing
SBCE, CTE, SBFT and ileocolonoscopy using a consensus clinical
diagnosis as the reference standard, the sensitivity of SBCE and
CTE was identical but the specificity of SBCE was lower.90
Some predictive markers of small bowel Crohn's disease
have been described to improve specificity, including weight
loss,273 perianal disease,274 raised inflammatorymarkers275–278
and faecal calprotectin,279–282 although none of these have
been validated in prospective trials. Conversely, in patients
with abdominal pain or chronic diarrhoea alone, capsule
endoscopy rarely results in the detection of clinically relevant
lesions in the small bowel.283–285 The International Conference
on Capsule Endoscopy (ICCE)286 recommended that patients
with suspected Crohn's disease should be selected to undergo
SBCE if they present with typical symptoms (chronic abdominal
pain, chronic diarrhoea, weight loss or growth failure) plus
either extraintestinal manifestations (fever, arthritis or
arthralgia, pyoderma gangrenosum, perianal disease or primary
sclerosing cholangitis), inflammatory markers (iron deficiency,
erythrocyte sedimentation rate, C-reactive protein, leuco-
cytosis or serology), or abnormal small bowel imaging (small
bowel series or CT scan). In a retrospective study of 56 patients
with suspected Crohn's disease, SBCE detected significant
lesions in 57.9% of those fulfilling two criteria and 77.8% when
3 or more criteria were met but only in 17.8% of those patients
who did not meet the ICCE criteria. Furthermore, Crohn's
disease was confirmed during follow-up in 21.4%, 52.6% and
77.8% of those patients, respectively.287manifestations, inflammatory markers and/or faecal
calprotectin [EL3] [Voting results: 100% agreement].11.3. SBCE in patients with established
Crohn's disease
Cross-sectional imaging with MRE or CTE is usually prefera-
ble to SBCE for evaluating the small bowel in patients with
established Crohn's disease, because of their potential to
identify obstructive strictures, assess the transmural nature
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presence of extraluminal disease.2 The risk of cumulative
radiation exposure should be taken into account when
selecting the cross-sectional imaging modality.ECCO Statement 11E
Cross sectional imaging with MR enterography or CT
enterography is usually preferable to small bowel
capsule endoscopy in patients with established Crohn's
disease as it can identify obstructive lesions, assess the
transmural nature of the disease and its anatomical
distribution, as well as the presence of extraluminal
disease [EL2] [Voting results: 93% agreement].
Table 11.1 Capsule Endoscopy Crohn's Disease Activity Index
(adapted from Niv Y et al.296).
A. Inflammation score
0 = None
1 = Mild to moderate edema/ hyperemia/ denudation
2 = Severe edema/ hyperemia/ denudation
3 = Bleeding, exudate, aphtae, erosion, small ulcer (b0,5 cm)
4 = Moderate ulcer (0.5–2 cm), pseudopolyp
5 = Large ulcer (N2 cm)In a recent meta-analysis,257 SBCE was superior to push
enteroscopy (PE), SBE/SBFT and CTE in the evaluation of
patients with established Crohn's disease, with a significant
higher yield (SBCE versus PE: 66% versus 9% (IY = 57%,
P b 0.00001, 95% CI = 43%–71%), SBCE versus SBE/SBFT: 71%
versus 36% (IY = 38%, P b 0.00001, 95% CI = 22%–54%), and
SBCE versus CTE: 71% versus 39% (IY = 32%, P = b0.0001, 95%
CI = 16%–47%). Conversely, SBCE diagnostic yield was inferior
to MRE: 70% versus 79% (IY of − 6%, P = 0.65, 95% CI = −30% to
19%). However, SBCE may enhance the detection of lesions in
the proximal small bowel when compared with both CTE and
MRE258,288 and has been shown to detect proximal lesions in up
to N50% of patients with previously diagnosed ileal Crohn's
disease.289 The clinical meaning of this incremental yield,
mainly for mild and more proximal lesions in patients with
previously established Crohn's disease remains to be deter-
mined. Currently the use of SBCE in this setting should be
reserved for selected clinical scenarios such as patients with
unexplained symptoms,290 iron deficiency anaemia or obscure
GI bleeding,291 when other investigations are inconclusive.
SBCE may also be considered in the assessment of postoper-
ative recurrence in those cases where ileocolonoscopy is
contraindicated or unsuccessful.292,293 The potential role of
SBCE in the assessment of mucosal healing after drug therapy
has also been investigated294 using quantitative scores such
as the Lewis score295 or the Niv score296 for clinical and
investigational purposes, which are similar to the existing
endoscopic scores for ileocolonoscopy, the CDEIS225 or
SES-CD.226 Finally, some retrospective studies highlighted
the potential impact of SBCE on the therapeutic management
of patients with established Crohn's disease,297–300 although
prospective controlled data on this topic are lacking.ECCO Statement 11F
The role of small bowel capsule endoscopy in patients
with established Crohn's disease should focus on
patients with unexplained iron deficiency or obscure
GI bleeding or in those with unexplained symptoms,
when other investigations are inconclusive [EL 5]
[Voting results: 100% agreement].11.4. Scoring systems for capsule endoscopy in CD
The use of a standardised quantitative scoring system to
describe the type, location and severity of small bowel
lesions has been proposed.301 The classic threshold of more
than 3 ulcers proposed by Mow et al.,302 which does not
assess the distribution or the severity of the inflammatory
activity, or take account of oedema or stenosis, has yielded
a positive predictive value of only 50% for the diagnosis of
Crohn's disease.272,303 The Capsule Endoscopy Crohn's Dis-
ease Activity Index (CECDAI) or Niv score has been recently
validated in a multicenter prospective trial.296,304 This
scoring index evaluates three parameters: inflammation
(A), extent of disease (B) and presence of strictures (C),
both for the proximal and distal segments of the small
bowel. The final score is calculated by adding the two
segmental scores: CECDAI = proximal ([A1 × B1] + C1) + distal
([A2 × B2] + C2)— Table 11.1.
When different types of lesions are identified in the same
bowel segment, only the more severe is considered to
calculate the score.
Another scoring index, the Lewis score,295,305 is based on
the number and distribution of intestinal segments with villous
oedema, ulceration and stenosis. Other endoscopic features
such as minor mucosal breaks, erythema, villous atrophy or
nodularity do not contribute to the score, because of
perceived lack of overall clinical significance and/or inability
to be judged objectively, resulting in low inter observer
agreement.295 To calculate the score, the small bowel is first
divided into equal thirds (tertiles), according to the transit
time of the capsule. For each tertile, a numeric subscore is
calculated, considering the extension and distribution of
oedema, and the number, size and distribution of ulcers. The
final score is the sum of the worst affected tertile plus the
score of stenosis (single/multiple, ulcerated/not ulcerated,
traversed/not traversed by the capsule) (Table 11.2).
An intuitive and user-friendly software application is
available for the automatic calculation of this score.305 The
Lewis score allows small bowel inflammatory activity to beB. Extent of disease score
0 = No disease
1 = Focal disease (single segment)
2 = Patchy disease (2–3 segments)
3 = Diffuse disease (more than 3 segments)
C. Stricture score
0 = None
1 = Single-passed
2 = Multiple-passed
3 = Obstruction (non-passage)
CECDAI = proximal ([A1 × B1] + C1) + distal ([A2 × B2] + C2)
Table 11.2 Lewis Score (adapted from Gralnek et al.305).
Parameters Number Longitudinal extent Descriptors
Villous appearance
(worst-affected tertile)
Normal—0 Short segment—8 Single—1
Oedematous—1 Long segment—12 Patchy—14
Whole tertile—20 Diffuse—17
Ulcer
(worst-affected tertile)
None—0 Short segment—5 b1/4–9
Single—3 Long segment—10 1/4–1/2–12
Few—5 Whole tertile—15 N1/2–18
Multiple—10
Stenosis
(whole study)
None—0 Ulcerated—24 Traversed—7
Single—14 Non-ulcerated—2 Not traversed—10
Multiple—20
LEWIS SCORE = Score of the worst affected tertile [(villous parameter × extent × descriptor) + (ulcer number × extent × size)] + Stenosis
Score (number × ulcerated × traversed).
Longitudinal extent: Short segment: b10% of the tertile; Long segment: 11% to 50% of the tertile; Whole tertile: N50% of the tertile.
Ulcer number: Single: 1; Few: 2–7; Multiple: ≥8.
Ulcer descriptor (size) is determined by how much of the capsule picture is filled by the largest ulcer.
ECCO Statement 11H
In patients with established Crohn's disease, cross-
sectional imaging or patency capsule should be per-
formed when small bowel capsule endoscopy is being
considered, in order to identify stenosis that may cause
capsule retention [EL2] [Voting results: 100% agreement].
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cant mucosal inflammatory change (LS b 135); 2) mild disease
(135 ≤ LS ≤ 790); and 3) moderate to severe disease
(LS N 790). In a population of patients with suspected Crohn's
disease, the diagnosis was confirmed during the follow-up in
82.6% of those with significant inflammatory activity on SBCE
(Lewis score ≥ 135), but in only 12.1% of those with a score
lower than 135.287 However, it is important to recognise that
inflammatory activity reported by all the scoring systems
independently of its etiology306 and as such SBCE on its own
cannot be used to diagnose Crohn's disease, irrespective of the
scores.
11.5. SBCE in patients with colonic inflammatory
bowel disease type unclassified (IBDU)
In up to 10% of adult patients with IBD affecting the colon, it
may be impossible to distinguish between Crohn's disease
and ulcerative colitis after ileocolonoscopy and small-bowel
imaging307,308 and therefore SBCE may be important
to establish a definite diagnosis in these patients with
IBDU.309–311 SBCE has demonstrated small bowel lesions
compatible with Crohn's disease in 17%–70% of patients with
IBDU or indeterminate colitis, although their clinical
significance may be unclear.309,310 A negative SBCE cannot
definitely exclude a future diagnosis of Crohn's disease.40,312
11.6. Small bowel and colon capsule endoscopy in
patients with Ulcerative Colitis
ECCO Statement 11G
To date, there is insufficient data to support the use of
small bowel or colon capsule endoscopy in the diagnostic
work-up or in the surveillance of patients with Ulcerative
Colitis [EL5] [Voting results: 100% agreement].
The diagnosis of Ulcerative Colitis relies on a combination
of clinical symptoms, laboratorial evaluation and typicalendoscopic and histopathologic features.76 However, where
there is diagnostic difficulty such as in patients with atypical
symptoms, rectal sparing, caecal patch or macroscopic
backwash ileitis, SBCE may aid diagnosis.43 Moreover, SBCE
may be useful in the investigation of patients with ulcerative
colitis and unexplained iron deficiency anaemia.313 In a
study looking at the value of SBCE in patients undergoing
pouch surgery314 no association was observed between the
findings of preoperative SBCE and development of pouchits
or Crohn's disease within the pouch over a 12-month period
after IPAA. A further study evaluating the role of preoper-
ative SBCE in 20 patients with ulcerative colitis and IBDU315
suggested that the presence of small bowel lesions prior to
colectomy does not predict the outcome after colectomy.2
Colon capsule endoscopy (CCE) was compared with
conventional colonoscopy in patients with Ulcerative Colitis.
In one study of 10 patients with ulcerative colitis, standard
colonoscopy was significantly better in assessing disease
activity compared to CCE.316 Another study enrolled 100
patients suspected or known to have UC.317 The sensitivity of
CCE in detecting active colonic inflammation was 89% and
the specificity was 75%, with positive and negative predic-
tive values of CCE for colonic inflammation of 93% and 65%,
respectively. The authors concluded that although CCE is a
safe procedure to monitor mucosal healing in ulcerative
colitis, at this stage it cannot be recommended to replace
conventional colonoscopy.11.7. Capsule retention in IBD
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Crohn's disease without obstructive symptoms and without
history of small bowel resection or known stenosis is low and
comparable to that of obscure GI bleeding.318–321 Cheifetz
et al.319 reported a retention rate of 13% in patients with
established Crohn's disease, but only 1.6% in patients with
suspected Crohn's disease. In this setting, routine small
bowel imaging or patency capsule prior to capsule endoscopy
is not mandatory. The cost-effectiveness of performing
SBCE immediately after ileocolonoscopy or only after small
bowel imaging has been investigated, with conflicting
results.322,323
In patients with established Crohn's disease, the risk of
small bowel capsule retention is increased, particularly in
those with a history of obstructive symptoms or known
intestinal stenosis.318–321,324 Therefore, cross-sectional
imaging or a patency capsule should be performed when
SBCE is being considered, to identify stenosis that may cause
capsule retention.325 One retrospective study compared the
performance of the patency capsule and radiological
examinations to detect clinically significant small bowel
strictures.326 Both methods were equivalent, suggesting that
if findings show no stricture or the patency capsule is
excreted intact, the patient will most likely pass the regular
capsule safely. In the event of capsule retention, it can often
be managed conservatively. The capsule may be retrieved
by device-assisted enteroscopy327,328 when conservative
measures to enable spontaneous passage fail, and only a
minority of patients will warrant surgery to retrieve the
capsule.329,33012. Device-assisted enteroscopy in IBD
ECCO Statement 12A
In patients with negative endoscopy and suspicion of
Crohn's disease on MRI or small bowel capsule endos-
copy, device-assisted enteroscopy may be performed if
diagnosis needs to be confirmed endoscopically and
histologically [EL 3] [Voting results: 100% agreement].
ECCO Statement 12B
Device-assisted enteroscopy may be performed in
expert hands if endoscopic therapy is indicated,
including dilatation of strictures, retrieval of impacted
capsule, treatment of bleeding [EL 4] [Voting results:
100% agreement].In 43–60% of patients with established Crohn's disease and
suspected small bowel involvement the lesions couldn't beassessed by means of conventional endoscopy.331–335 Diag-
nostic yield of device assisted enteroscopy (DAE) when
evaluating patients with suspected Crohn's disease varies
between 22% and 70%.333,336–338 The diagnostic yield is
higher if the indication for DAE was based on one or more
previous investigations compared to procedures done with-
out prior examinations (77.8% versus 60% respectively).338
Prospective trials compared DAE to other imaging modalities
such as MRE and SBCE. There was an acceptable correlation
of 88–75% and 67% respectively although SBCE was not
performed when stenosis was suspected.339,340 Because of
the invasive nature of DAE it should only be performed if it
alters therapeutic strategy. Step up therapy in Crohn's
disease based on a positive DAE has a proven clinical impact
as was demonstrated in a prospective trial.334,335,341 Small
bowel inflammation was demonstrated in 75% of the patients
with established Crohn's disease and previous negative
conventional endoscopy. In 74% of these patients, treatment
was adjusted and resulted in clinical remission at 1 year and
a significant decrease in CDAI. In another subgroup,
endoscopic reevaluation with DAE demonstrated mucosal
healing or improvement in the Index score in 90%335
of patients. Overall, DAE is safe in the assessment of
the small bowel in both the adult and paediatric population
with (suspected) Crohn's disease.333,341 The advantages
of DAE compared with SBCE include the evaluation of
atypical lesions, the ability to obtain biopsies for histopa-
thology, and the potential for therapeutic intervention.
Treatment of Crohn's related strictures in experienced
hands is reported to be safe and effective.205,342 Strictures
suitable for dilation are: b4 cm, non-inflammatory and
non-angulated. See ECCO statement 8A and accompanying
text.13. Endoscopy for dysplasia and CRC detection
in IBD
13.1. Epidemiology
People with longstanding ulcerative colitis (UC) have a
higher risk of developing colorectal cancer (CRC) than the
general population. Initial estimates were based on the
meta analysis by Eaden et al. of 116 studies including
population-based and hospital-based cohorts.343 They
found the overall prevalence of UC-CRC to be 3.7%. In a
large Swedish population-based study, Ekbom found a
standardised incidence ratio (SIR) of 5.7 (95% CI 4.6–7.0).344
However the magnitude of risk in recent population-
based studies appears smaller than in earlier studies: the
more recent Swedish population-based study by Soderlund
found a SIR of 2.3 (95% CI 2.0–2.6)345; Bernstein's population-
based study found increased incidence rate ratios in UC
patients of 2.75 (95% CI 1.91–3.97).346 Two studies showed no
difference from the general population: Winther's study
from Denmark (where the historical colectomy rate is
high compared to the rest of the world) had standardised
morbidity ratio no different from the general population
(SMR, 1.05; 95% CI, .56–1.79).347 Jess's study from the USA
found a SIR of 1.1 (95% confidence interval [CI], 0.4–2.4).348
A more recent meta-analysis of population-based cohort
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2.4-fold.349
The reasons for the apparent reduced risk of CRC over
time is unclear but may include early study selection bias,
improved control of mucosal inflammation, more extensive
use of 5-ASA compounds, the implementation of surveillance
programmes and timely colectomy.350 Differences in the
proportion of patients with proctitis (as opposed to more
extensive disease) may also account for some of the variation
in CRC incidence.
The CRC risk appears to be the same in Crohn's colitis
given the extent of colonic involvement.351,352 Ekbom
showed that patients with terminal ileal Crohn's had the
same risk of CRC as the general population but those with
colonic Crohn's had a relative risk (RR) of 5.6 (95% CI 2.1–
12.2).353 Bernstein's Canadian population-based study found
a similar risk for CRC in all patients with Crohn's disease (RR
2.64; 95% CI 1.69–4.12) and UC (RR 2.75; 95% CI 1.91–
3.97).346 They found the risk of rectal cancer to be increased
in UC (RR 1.90; 95% CI 1.05–3.43) but not in Crohn's colitis
(RR 1.08; 95% CI 0.43–2.70). Soderlund found a SIR of 2.1
(95% CI 1.2–3.4) in Crohn's.34513.2. Risk factors
ECCO Statement 13A
Patients with longstanding ulcerative colitis and
Crohn's colitis have an increased risk of colorectal
cancer (CRC) compared to the general population [EL2]
[Voting results: 93% agreement].
A longer duration of colitis is associated with an increased
risk of IBD-CRC. Older reports included in two meta-
analyses confirmed an exponential increase in the risk
after ten years of UC343,354: Eaden showed a cumulative
CRC risk of 2% at 10 years, 8% at 20 years, and 18%
after 30 years of disease. The mean duration of colitis at
the time of IBD-CRC diagnosis was 16.3 years (95% CI 15.0–
17.6).
However more recent population based studies have
suggested a much lower risk of IBD-CRC. The annual
incidence has been found to be as low as 0.06–0.20% and
cumulative risk at 30 years to be as low as 2%.346,347,355–357
In the largest report of surveillance colonoscopy in
patients with extensive UC, the cumulative incidence of
CRC by colitis duration showed a linear rather than
exponential increase, from 2.5% at 20 years to 10.8% at
40 years of extensive UC.358 Rutter found the median
duration of UC at diagnosis of CRC was 23.5 years (range
11–48). Lakatos's Hungarian population-based study calcu-
lated a cumulative risk of 0.6% after 10 years, 5.4% after
20 years and 7.5% after 30 years.
Although IBD-CRC is comparatively rare before 8 years
of colitis, Lutgens calculated that 17–22% of patients
developed cancer before the starting points for surveillance(8–10 years from onset of symptoms for extensive colitis
and 15–20 years for left-sided disease).359
ECCO Statement 13B
Colorectal cancer risk is highest in patients with
extensive colitis, intermediate in patients with left-
sided colitis, and lowest in proctitis [EL2].
Patients with severe inflammation, patients with
colitis-associated primary sclerosing cholangitis (PSC),
and patients with a family history of CRC may have a
particularly increased risk [EL2] [Voting results: 100%
agreement].
Several independent factors affect the magnitude of CRC
risk. The colonic extent of mucosal inflammation is the best
established and has been correlated with CRC risk in several
studies, along with a systematic review.239,344,345,348,354,356,360
Risk is highest in those with pancolitis: Ekbom calculated a SIR
for CRC of 1.7 for proctitis (non significant), 2.8 for left-sided
colitis, and 14.8 for pancolitis, as compared with the general
population.344 Again, more recent population-based studies
indicate a lower magnitude of increased risk (SIR 5.6 for
pancolitis, 2.1 for Crohn's colitis and 1.7 for proctitis [all
significant]).345 It seems reasonable to assume that patients
with Crohn's colitis involving only one segment of colo-rectum
should not be considered to be at risk of CRC.361
How disease extent is measured is important; earliest
studies used radiological evidence (barium enemas), more
recent studies have used endoscopic or histological evi-
dence. This may in part explain the apparent differing
cancer risk over time.
IBD-CRC is thought to occur in the context of inflamma-
tion. Although early studies showed no clear association
between colitic symptoms and CRC risk, this may be
explained by the recognised poor correlation between
patients' symptoms and the severity of inflammation. Recent
studies have focused on severity of inflammation at a tissue
level. Rutter's case-control study found a significant corre-
lation between both colonoscopic (OR = 2.5; P b 0.001) and
histological (OR = 5.1; P b 0.001) inflammation and neopla-
sia risk.239 Gupta's cohort study also found a significant
relationship between histological inflammation over time
and progression to advanced neoplasia (hazard ratio 3.0; 95%
CI1.4–6.3).362 In a further study, Rutter found that mucosal
healing may decrease neoplasia risk: macroscopically normal
mucosa appears to return the CRC risk to that of the general
population.237
Post-inflammatory polyps (PIPs) develop during the healing
phase of severe inflammation. Their presence has been
associated with an increased risk of CRC in two case control
studies, probably reflecting the increased risk of previous
severe inflammation rather than themselves having malignant
potential. Rutter found that cases of CRC were significantly
more likely to have PIPs than the controls (OR 2.14; 95% CI 1.24–
3.70).237 Velayos showed the presence of PIPs was associated
with double the CRC risk (OR 2.5; 95% CI: 1.4–4.6).363
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Soetikno's meta-analysis of 11 studies concluded that
patients with UC-PSC were at increased risk of CRC
compared with patients with UC alone (OR 4.09; 95% CI
2.89–5.76).364 Cancers often occur earlier in a patient's
disease; one explanation is that patients with PSC often have
milder colonic inflammation and may have had subclinical
inflammation for years before colitis diagnosis, however one
would also expect the milder inflammation to confer a
relatively low risk. Other hypotheses for the increased risk
include shared genetic susceptibility to PSC and CRC, and
the effect of an altered bile salt pool.
Family history of CRC contributes to the risk of CRC in
patients with colitis. Both case control and population-based
studies show a 2–3 fold increase.365 Askling found that a
family history of CRC was associated with a 2.5 fold RR of
IBD-CRC (95% CI 1.4–4.4) and those with a 1st-degree
relative diagnosed with CRC before 50 years of age had a
higher risk (RR 9.2; 95% CI 3.7–23).366 Velayos also found
family history of CRC to be an independent risk factor for
IBD-CRC in patients with UC (OR 3.7; 95% 1.0–13.2).363
Young age at diagnosis may be an independent risk factor
for IBD-CRC,349 although data are inconsistent. Interpreta-
tion of retrospective studies is complex as children tend to
have more extensive and more severe colitis, and those
diagnosed at a young age have the potential for longer colitis
duration,367 itself a risk factor. Ekbom found age at diagnosis
to be an independent risk factor for CRC.344 After adjusting
for the extent of disease an adjusted SIR of 0.51 was seen for
each increase in age group at diagnosis. Other studies have
not confirmed this association. In Rutter's 30 year study,
patients who developed CRC had a higher median age of
onset of disease than those not developing cancer.358
Greenstein et al. found that the CRC risk was higher in
patients diagnosed with IBD above 30–40 years of age
compared with those diagnosed below 20 years old.368 In
Eaden's meta-analysis, in adult patients a negative trend
(non-significant) between younger age at onset and in-
creased risk of CRC was seen.343 In children, the cumulative
risk of CRC over time was higher than the corresponding
rates for adults. Winther found the time between onset of
colitis and the development of IBD-CRC to be the same in
young and old patients.347 Karvellas found that patients
diagnosed with UC over the age of 40 years developed CRC
more quickly than younger patients.369
13.3. Endoscopy in surveillance
ECCO Statement 13C
Surveillance colonoscopy permits detection of dysplasia
and earlier detection of CRC,whichmay lead to improved
prognosis [EL4] [Voting results: 100% agreement].
13.3.1. Benefit of surveillance
Surveillance colonoscopy programmes aim to reduce mor-
bidity and mortality due to CRC by detecting cancer at anearlier stage with better prognosis or by detecting and re-
secting dysplasia, reducing CRC incidence.
The reduced CRC incidence seen in recent studies may be
evidence that surveillance is effective although other
potential factors including better disease control may be
relevant. The effectiveness of surveillance has been system-
atically reviewed by the Cochrane collaboration.354 Limiting
their analysis to studies that included a control group, the
authors were unable to demonstrate a benefit of surveil-
lance programmes for preventing CRC-related death in UC.
However only two studies met their inclusion criteria.370,371
Lutgen's larger and more recent study showed improved
survival from colonoscopic surveillance in IBD patients by
detecting CRC at a more favourable tumour stage: 5-year
CRC-related survival rate of patients in the surveillance
group was 100% compared with 74% in the non-surveillance
group (P = 0.042).372 In the surveillance group, one patient
died as a consequence of CRC compared with 29 patients
in the control group (P = 0.047). In addition, more early
tumour stages were found in the surveillance group (P =
0.004).
Three retrospective case control studies have shown a
correlation between the use of surveillance colonoscopy
and reduced odds ratio for CRC.363,373,374 All these studies
could be subject to lead-time or selection bias; thus in the
absence of a prospective randomised controlled trial,
unequivocal evidence for the benefit of these programmes
is lacking.
Benefit estimated in years of life saved may be much
greater in colitis patients than for general population
screening because IBD-CRC tends to occur earlier in life
and modelling has evaluated that life saved per case
screened ranges from 1.2 to 5 years in UC patients, compared
to 1.2 to 4 months in general population screening.354,375
These issues should be discussed with patients before
surveillance commences.13.3.2. Timing and interval of endoscopic surveillance
ECCO Statement 13D
Screening colonoscopy should be offered at estimated
8 years after the onset of colitic symptoms to all
patients to reassess disease extent [EL5] [Voting
results: 100% agreement].
As duration of disease is a major risk factor for the de-
velopment of IBD-CRC, it is rational to propose a screening
colonoscopy when the risk starts to increase, i.e. after
8–10 years from the onset of disease.343 This initial
colonoscopy also aims to reassess the extent of disease,
since this parameter also impacts on the risk of CRC.
Nevertheless, the appropriateness of screening colonoscopy
as a way of reassessing disease extent and potential risk has
not been formally established. It has been proposed in
reviews and a prior consensus report,376 as well as being
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participating experts.ECCO Statement 13E
Ongoing surveillance should be performed in all
patients apart from those with proctitis or Crohn's
colitis involving only one segment of colorectum [EL4]
[Voting results: 100% agreement].
As there is no clear evidence for surveillance intervals,
individualising intervals based on risk stratification is
recommended [EL5] [Voting results: 100% agreement].
a) Patients with high risk features (stricture or
dysplasia detected within the past 5 years, PSC,
extensive colitis with severe active inflammation,
or a family history of CRC in a first degree relative
at less than 50 years) should have next surveil-
lance colonoscopy scheduled for 1 year [EL4]
[Voting results: 93% agreement];
b) Patients with intermediate risk factors should
have their next surveillance colonoscopy sched-
uled for 2 to 3 years. Intermediate risk factors
include extensive colitis with mild or moderate
active inflammation, post-inflammatory polyps or
a family history of CRC in a first degree relative at
50 years and above [EL5] [Voting results: 100%
agreement];
c) Patients with neither intermediate nor high risk
features should have their next surveillance
colonoscopy scheduled for 5 years [EL4] [Voting
results: 93% agreement].The surveillance schedule should take into account the
risk for dysplasia to progress to CRC between two
surveillance interventions. However, the timing of dyspla-
sia progression is not known in IBD. Therefore, intervals
between repeat surveillance colonoscopy should be
prospectively adjusted to each patient according to
CRC risk factors and previous colonoscopic findings.377
Disease extent should be taken as the most extensive
histologically-confirmed inflammation from all previous
colonoscopies.
There is consistent evidence that individuals who have
had high-grade dysplasia (HGD) are at increased risk of
CRC.358,378 The data for low-grade dysplasia (LGD) are less
consistent: although most studies show an increased CRC
risk, some do not.379–383 In a recent meta-analysis,
LGD was found to be associated with a 12-fold risk of
developing advanced neoplasia and a 9-fold increased risk
of developing CRC.384 Thus it seems appropriate that all
patients with dysplasia (within the past 5 years) irrespec-
tive of grade, should undergo annual colonoscopic surveil-
lance. Since CRC has been observed within 2 years of
surveillance colonoscopy, yearly colonoscopy is recom-
mended in patients with high risk features.383,385 Five-
yearly colonoscopy is recommended for patients with
extensive colitis with no other risk factor.237,377 Two to
three-yearly colonoscopy is recommended in patients withintermediate risk.377 Wherever possible, surveillance colo-
noscopies should be performed during disease remission to
aid discrimination between inflammatory and neoplastic
changes. However, surveillance should not be delayed in
those with chronic active colitis as these patients have a
higher neoplasia risk.239,362
13.3.3. Strategies to optimise surveillance
ECCO Statement 13F
Effective bowel preparation, meticulous inspection
during slow withdrawal and the use of high resolution
endoscopic equipment are preferred for optimal neopla-
sia detection [EL4][Voting results: 100% agreement].
In recent years, endoscopic equipment, patient prep-
aration and diagnostic technique have advanced consid-
erably. High resolution equipment improves image quality
and these instruments may improve dysplasia detection
rate. A recent colitis surveillance study showed that
high definition colonoscopy improved dysplasia detection
compared to standard definition.386 Achieving optimal
colonic preparation is needed for chromoendoscopy and
longer withdrawal time yields higher adenoma detection
rates in non-IBD patients.387 In addition longer procedure
duration may be associated with increased dysplasia
detection388.
ECCO Statement 13G
Pan-colonic methylene blue or indigo carmine chromo-
endoscopy should be performed during surveillance
colonoscopy, with targeted biopsies of any visible
lesion [EL2].
If appropriate expertise for chromoendoscopy is not
available, random biopsies (4 every 10 cm) should be
performed [EL3]; however this is inferior to chromo-
endoscopy in the detection rate of neoplastic lesions
[EL2] [Voting results: 100% agreement].
The dysplasia yield from surveillance colonoscopy can
be improved by spraying dyes that highlight subtle
changes in the architecture of the colonic mucosa.389–395
This holds true for all dysplastic lesions, the proportion
of targeted lesions and the proportion of flat lesions
detected.
With this method, random biopsies of apparently normal
mucosa are of negligible additional value.394,396 Com-
parable diagnostic yields from chromoendoscopy have
been obtained with both methylene blue and indigo
carmine.389–395
A meta-analysis including six studies (1277 patients)
showed that the difference in dysplasia yield between
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(95% CI 3.2–11.3) on a per patient analysis (NNT 14.3).397
The absolute difference in lesions detected by targeted
biopsies was 44% (95% CI 28.6–59.1) and flat lesions was
27% (95% CI 11.2–41.9) in favour of chromoendoscopy.
Chromoendoscopy also aids discrimination between neoplas-
tic and non-neoplastic changes, based on the surface crypt
architecture (pit pattern). Another meta-analysis looked at
the diagnostic accuracy of chromoendoscopy compared to
histology and reports a sensitivity of 83.3% and specificity
91.3% for chromoendoscopy in detection of intraepithelial
neoplasia.398
Although chromoendoscopy takes significantly longer
than conventional colonoscopy,398 it not only improves the
dysplasia yield but has potential to reduce pathology
workload as fewer biopsies are needed.
ECCO Statement 13H
Other image enhancement techniques such as narrow
band imaging or autofluorescence have not been
convincingly demonstrated to be superior to white
light endoscopy or chromoendoscopy in the detection
of neoplastic lesions, thus they cannot currently be
recommended for colitis surveillance [EL2] [Voting
results: 93% agreement].Narrow band imaging (NBI) is a technology which
highlights vessel and crypt architecture by altering the
light which is emitted to the mucosa. None of the three
randomised trials using first generation399 and second
generation400,401 endoscopes (including high resolution)
which analysed the value of NBI compared to WLE399–401
identified any benefit for NBI detecting colitis associated
dysplasia. NBI was also unsatisfactory for differentiating
neoplastic from non-neoplastic mucosa. A single cross-over
prospective randomised trial comparing narrow-band imag-
ing with chromoendoscopy could not identify a clear benefit
for NBI.402
A prospective randomised trial analysing the value of
Endoscopic tri-modal imaging (ETMI), which incorporates
WLE, NBI and autofluorescence imaging (AFI)403 suggested
ETMI was superior to WLE, but further studies are still
awaited to confirm this single study.
Endomicroscopy is an emerging technology which provides
in vivo histology during ongoing colonoscopy. The technique
requires the additional use of contrast agents. Fluorescein-
based endomicroscopy is mainly used and proved to be safe
and highly accurate analysing intraepithelial neoplasia.404 Two
prospective and randomised trials have evaluated the value
of endomicroscopy in addition to chromoendoscopy.391,405
Here endomicroscopy was able to significantly reduce the
number of biopsies while retaining the diagnostic yield of
chromoendoscopy.
Endomicroscopy cannot widely screen the colonic mucosa.
It is mainly used to analyse colorectal lesions once they have
been detected and thus reduces the amount of biopsies.Endomicroscopy is highly examiner dependent and time
consuming and cannot be broadly recommended. Neverthe-
less endomicroscopy has future potential because it allows
functional and molecular imaging.
13.4. Diagnosis of dysplasia
ECCO Statement 13J
A finding of dysplasia should be confirmed by an
independent gastrointestinal specialist pathologist
[EL2] [Voting results: 100% agreement].
The grade of dysplasia is important because it impacts on the
sensitivity and specificity of the presence or future devel-
opment of CRC. However histopathological analysis is a
qualitative test and interobserver variation for the grading
of dysplasia is high, particularly for LGD and where there is
background inflammation.383,406,407 Individual studies do not
show an increased risk of malignant transformation in
LGD379,380 or an even higher risk.408,409 However, in a recent
meta-analysis, LGD was found to be associated with a 12-fold
risk of developing advanced neoplasia and a 9-fold increased
risk of developing CRC.384 For this reason, dysplasia should
be confirmed by an experienced gastrointestinal specialist
pathologist.
ECCO Statement 13K
A visible lesion with dysplasia should be completely
resected by an experienced endoscopist, irrespective
of the grade of dysplasia or the localisation relative to the
inflamedmucosal areas. In the absence of dysplasia in the
surrounding mucosa, ongoing meticulous colonoscopic
surveillance is appropriate [EL1].
If endoscopic resection is not possible or if dysplasia is
found in the surrounding flat mucosa, proctocolectomy
should be recommended [EL4] [Voting results: 100%
agreement].
Most dysplasia is visible at colonoscopy,410–412 even with
standard resolution endoscopes. Raised dysplastic lesions
on a background of colitis (formerly referred to as DALMs)
have until recently been considered an indication for
colectomy. In the context of colitis surveillance, the term
“flat lesion” has traditionally been used for endoscopically
invisible dysplastic lesions diagnosed by random biopsies.
Both these terms are confusing and should abandoned,
especially as the term “flat” now has an entirely different
endoscopic definition (Paris endoscopic classification).413 It is
preferable to use the terms endoscopically visible and
non-visible lesions, since it is increasingly recognised that
well-circumscribed visible lesions may be amenable to
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location within or outside areas of documented UC and
irrespective of the presence of LGD or HGD. This applies
also for sporadic adenomas in the context of colitis.419 If
the polypectomy is confirmed complete by histology,
biopsies obtained from the flat mucosa immediately adjacent
to the polypectomy site show no dysplasia and no dysplasia
is found elsewhere in the colon, a careful colonoscopic
follow-up preferably with chromoendoscopy at 3 months
before reverting to annual surveillance is recommended,
because at least half of such patients may developed
further lesions.415–417 However, the risk of developing
cancer has not been found to be elevated under careful
surveillance,410,414,416,417,419–421 as confirmed in a recent
meta-analysis.422 If the lesion is not resectable, or is
associated with dysplasia in the adjacent mucosa, then
colectomy is indicated due to the high risk of concomitant
CRC.410,423
ECCO Statement 13L
Where dysplasia of any grade is found without an
associated endoscopically visible lesion, urgent repeat
chromoendoscopy should be performed by an experi-
enced endoscopist to determine whether a well-
circumscribed lesion exists and to assess for synchro-
nous dysplasia [EL5] [Voting results: 100% agreement].
Adenocarcinoma or HGD without an associated endo-
scopically visible lesion are indications for surgery
[EL3] [Voting results: 100% agreement].
A patient with confirmed LGD detected in mucosa
without an associated endoscopically visible lesion
should undergo repeat chromoendoscopic colonoscopy
with additional random biopsies within 3 months [EL5]
[Voting results: 93% agreement].Once dysplasia is found and cannot be treated endoscop-
ically proctocolectomy should be performed because the risk
of CRC is appreciably increased384 assuming that the biopsies
were indeed random biopsies and not targeted biopsies. If
LGD is detected, the 9-fold increased risk of developing CRC
reported in the most recent meta-analysis384 may be
reasonably be viewed as justification for proctocolectomy
as well.378 However, because some follow-up studies of
patients with LGD have shown a low rate of CRC develop-
ment,379,380,383 it seems a reasonable alternative to contin-
ue intensified colonoscopic surveillance in those who will
adhere strictly to the surveillance programme. However, as
this remains controversial in the literature354,379,409 to offer
definitive guidance, we recommend multidisciplinary team
discussion and also detailed discussion with the patient.
When electing for surveillance, we recommend an additional
chromoendoscopic procedure to check the resected site and
to double-check the remaining colon at around 3 months; in
this instance (and for this procedure alone), extensive
random biopsy sampling may be prudent.13.5. Pouch surveillance
ECCO Statement 13M
Following proctocolectomy, patients with any of the
following features are at increased risk of developing
rectal cuff or pouch neoplasia [EL3]:• Previous dysplasia or cancer
• PSC
• Type C mucosa of pouch (persistent atrophy &
severe inflammation)
[Voting results: 100% agreement].
Dysplasia following restorative proctocolectomy with ileal
pouch anal anastomosis (IPAA) is rare but can develop in
either the ileal pouch mucosa or any retained anorectal
mucosa (the ‘anal transition zone’). Cancers reported in
the literature occurred over 10 years after the onset of
UC.424 Dysplasia risk factors include previous dysplasia
or CRC, longer rectal cuff and PSC.425,426 Type C pouch
mucosa (permanent persistent atrophic mucosa with severe
inflammation) has a greater tendency to develop colonic
type metaplasia427,428 and thus both type C mucosa and
refractory pouchitis are associated with a higher risk of
neoplasia although the absolute risk remains small.429 The
occurrence of neoplasia is extremely rare in the absence of
these risk factors.430 So far no clear evidence that pouch
surveillance is beneficial. However if a clinician wishes to
offer surveillance, annual pouch surveillance by flexible
sigmoidoscopy, taking four proximal and four distal pouch
biopsies, would seem reasonable377 in those with high risk
features and every 5 years in those without high risk
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